Podcasts about GSK

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest breakthroughs and trends shaping the landscape of medicine and treatment. In the realm of weight management and metabolic disorders, significant advancements are underway. Roche and Zealand Pharma have moved Petrelintide, an amylin analog, into a Phase 3 clinical trial after a promising Phase 2 showing a nearly 10% weight loss in participants. This development highlights an increasing focus on protein-based therapies for metabolic conditions, offering new hope for tackling obesity—a major global health challenge. Similarly, Eli Lilly's Retatrutide has made headlines with its Phase 3 trial results, demonstrating a remarkable 25% body weight reduction in obese patients with type 2 diabetes. This triple agonist targets multiple receptors, marking a novel approach in metabolic therapeutics that could transform obesity and diabetes management by targeting key pathways regulating energy balance and glucose levels. In oncology, Pierre Fabre and Atara Biotherapeutics have resubmitted their Biologics License Application for Ebvallo (tabelecleucel) to the FDA. This follows successful Phase 3 trials targeting Epstein-Barr virus-positive post-transplant lymphoproliferative disease, a severe complication post-transplantation. If approved, tabelecleucel could provide a critical allogeneic T-cell therapy option for these patients, underscoring the evolution of cell-based therapies in cancer treatment. Regulatory news is also making waves with Segetis Therapeutics receiving FDA approval for Emcitate (tiratricol), designed to treat monocarboxylate transporter 8 deficiency. This approval is particularly significant as it marks the first U.S. treatment for this rare pediatric thyroid hormone disorder, showcasing the industry's dedication to addressing rare diseases' unmet needs. Meanwhile, artificial intelligence continues to reshape drug discovery and development processes. Collaborations such as GSK's with Wave Life Sciences on hepatic siRNA programs and Novartis Biomedical Research's partnership with CAS aim to enhance drug discovery workflows through advanced data analytics and machine learning models. In clinical trial news, Highlight Therapeutics reported successful Phase 2 results for BO-112 in high-risk head and neck basal cell carcinoma. The immunotherapy showed efficacy as an intralesional therapy, providing new hope for patients at high risk of cancer recurrence or progression. Furthermore, Amgen's Daxdilimab demonstrated positive outcomes in a Phase 2 trial for discoid lupus erythematosus by significantly reducing disease severity, highlighting interest in targeted therapies for autoimmune conditions. Connect Biopharma's Rademikibart has shown promise in reducing exacerbations of chronic obstructive pulmonary disease during its Phase 2 trial. As an IL-4/IL-13 inhibitor, it stands as a potential competitor to existing treatments like Dupixent, potentially reshaping therapeutic strategies in respiratory diseases. These advancements reflect broader trends within the pharmaceutical industry towards personalized medicine, innovative drug mechanisms, and strategic partnerships leveraging AI and advanced analytics. As these therapies progress through clinical trials and regulatory pathways, they hold promise for enhancing patient care and expanding treatment options across various disease areas. In related regulatory developments, the European Commission has revoked marketing authorization for Hansoh Pharma's Aumseqa following a legal challenge by AstraZeneca. This decision underscores the competitive nature of oncology and highlights the importance of patent disputes and regulatory compliance in maintaining market presence. On the corporate strategy front, PhRMA has appointed former House Majority Leader Eric Cantor as its CEO. This move indicates PhRMA's focus on navigating complex regulatory environments crucial for shaping healthcare policies impacting drug development and pricing. The White House is also taking steps to address global supply chain vulnerabilities by boosting domestic production of essential medicines—a strategy aimed at enhancing national security while ensuring a steady supply of critical drugs. In industry funding news, NorthStar Medical Technologies secured $185 million to advance radiopharmaceutical isotope production. With commercial-scale manufacturing of Actinium-225 completed earlier this year, NorthStar is set to significantly increase capacity by year-end—reflecting growing demand within precision medicine. In space-based innovations, Varda Space Industries raised $251 million to fuel pioneering drug manufacturing using reusable rockets in Earth's low orbit—potentially revolutionizing drug production by utilizing microgravity environments. Finally, recent developments highlight challenges within the industry as well. Companies like Novo Nordisk and BioMarin face layoffs amid evolving market demands. Meanwhile, Enanta Pharmaceuticals downsizes amid forthcoming antiviral readouts—a reflection of broader strategic pivots required to remain competitive. These developments underscore an era where scientific breakthroughs are rapidly transforming drug development paradigms. As companies navigate intellectual property challenges and strategic collaborations continue to drive innovation aimed at addressing diverse unmet medical needs across therapeutic areas, stakeholders are likely to witness continued growth and transformation in drug development and delivery paradigms worldwide. Thank you for joining us on Pharma Daily—your go-to source for insights into the ever-evolving pharmaceutical and biotech industries. Stay tuned for more updates as we continue to explore groundbreaking advancements shaping the future of medicine.Support the show

Grab a biccie & cuppa as we gossip about the GSK campaign complaints (Cases: 0269, 0568 & 0874) .... genuine gasps from Rina when Jean explains how the "courtesy copy" bit them in the bum

Listen to Jesus G. Berdeja, MD, and Ajai Chari, MD, as they discuss sequencing of antibody–drug conjugates (ADCs), bispecific antibodies, CAR T-cell therapy, and other novel treatment modalities for patients with relapsed/refractory multiple myeloma.Presenters:Jesus G. Berdeja, MDDirector of Myeloma ResearchGreco-Hainsworth Centers for Research PartnerTennessee OncologyNashville, TennesseeAjai Chari, MDProfessor of Clinical MedicineDirector of Multiple Myeloma ProgramUCSF Helen Diller Family Comprehensive Cancer CenterUniversity of California, San Francisco (UCSF) Medical CenterSan Francisco, CaliforniaContent based on an online CME program supported by an educational grant from GSK.Link to full program:https://bit.ly/3TZSmufGet access to all of our new podcasts by subscribing to the Decera Clinical Education Oncology Podcast on Apple Podcasts, YouTube Music, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Os avanços da ciência transformaram o tratamento dos cânceres hematológicos,ampliando as possibilidades terapêuticas e contribuindo para o aumento da sobrevida depacientes com doenças como o mieloma múltiplo. Ainda assim, diagnóstico, recaídas,acesso ao tratamento e qualidade de vida permanecem entre os desafios da jornada.¹ ⁴Neste episódio do podcast Notícia no Seu Tempo, a jornalista Carla Fiorio conversacom os hematologistas Walter Moisés Tobias Braga, médico responsável peloAmbulatório de Mieloma Múltiplo da Universidade Federal de São Paulo (SP 114081);e Deise Almeida (SP 149683), médica e diretora médica de Oncologia e Hematologia daGSK Brasil, sobre mieloma múltiplo e mielofibrose, duas doenças que fazem parte douniverso da onco-hematologia. A conversa aborda os avanços da medicina, asnecessidades que ainda não foram atendidas e as perspectivas para o futuro do cuidado. Este episódio é uma produção do Estadão Blue Studio com patrocínio da GSK.Referências para o texto de apresentação: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20).2. Hungria V, et al. Emerging Real-World Treatment Patterns and ClinicalOutcomes of Multiple Myeloma in Argentina and Brazil: Insights from theTOTEMM Study in the Private Healthcare Sector. Curr Oncol. 2026;33:16.3. Eisfeld C, et al. Time trends in survival and causes of death in multiple myeloma.BMC Cancer. 2023.4. IQVIA Institute. Global Oncology Trends 2025.Referências para o episódio: 1. Nooka AK, Kastritis E, Dimopoulos MA. Treatment options for relapsed andrefractory multiple myeloma. Blood. 2015;125(20). REF-480872. CA: A Cancer Journal for Clinicians. Vol. 70. 2020. p. 7–30. REF-724913. Kazandjian D. Multiple myeloma epidemiology and survival: A uniquemalignancy. Semin Oncol. 2016;43(6):676–81. REF-2960414. Hungria, V.; Maiolino, A.; Pessoa de Magalhães, R.J., Filho; Pitombeira deLacerda, M.; Remaggi, G.; Scibona, P.; Seehaus, C.; Brulc, E.; Savoy, N.; Fantl,D.; et al. Emerging Real-World Treatment Patterns and Clinical Outcomes ofMultiple Myeloma in Argentina and Brazil: Insights from the TOTEMM Studyin the Private Healthcare Sector. Curr. Oncol. 2026, 33, 16.https://doi.org/10.3390/curroncol33010016. REF-316596 5. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5thedition of the World Health Organization Classification of HaematolymphoidTumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia.2022;36:1703–1719. doi:10.1038/s41375-022-01613-1 REF-2279396. Eisfeld C. et al. Time trends in survival and causes of death in multiplemyeloma. BMC Cancer. 2023. REF-3161117. IQVIA Institute. Global Oncology Trends 2025. REF-3191028. Observatório de Oncologia. Panorama do Mieloma Múltiplo no SUS [acesso emjul2026]. https://observatoriodeoncologia.com.br/estudos/cancer-de-sangue/mieloma-multiplo/2024/panorama-do-mieloma-multiplo/ REF-2963359. International Myeloma Foundation Latin America. Mieloma múltiplo: segundotipo de câncer sanguíneo mais frequente no mundo [Internet]. São Paulo: IMFLA; 2022 jun 07 [acesso em jul2026]. https://myeloma.org.br/mieloma-multiplo-segundo-tipo-de-cancer-sanguineo-mais-frequente-no-mundo/. REF-26981910. Kumar SK et al. Multiple Myeloma. Nature Reviews Disease Primers. 2017.REF-1817111. Yu B et al. BCMA-targeted immunotherapy for multiple myeloma. Journal ofHematology & Oncology. 2020. REF-10177912. Wang R et al. Antibody–Drug Conjugates (ADCs): current and futurebiopharmaceuticals. Journal of Hematology & Oncology. 2025. REF-28457113. Scherber RM, Mesa RA. Management of challenging myelofibrosis after JAKinhibitor failure. Blood Reviews. 2020. REF-16832614. Nicolosi M et al. Sex and degree of severity influence the prognostic impact ofanemia in primary myelofibrosis. Leukemia. 2018. REF-30724015. Mughal TI et al. Myelofibrosis-associated complications. International Journalof General Medicine. 2014. REF-16520816. Naymagon L, Mascarenhas J. Myelofibrosis-Related Anemia: Current andEmerging Therapeutic Strategies. Hemasphere. 2017. REF-16521017. OJJAARA® (momelotinibe). Bula do produto; Consulta Pública ANS sobreincorporação para mielofibrose. REF-32111518. Hungria, V; et al. Belantamab mafodotin plus bortezomib and dexamethasone inpatients with relapsed or refractory multiple myeloma (DREAMM-7): updatedoverall survival analysis from a global, randomised, open-label, phase 3 trial.Lancet Oncol 2025 Published Online July 15, 2025 https://doi.org/10.1016/S1470-2045(25)00330-4. REF-24715319. Mukhopadhyay, P., Abdullah, H.A., Opalinska, J.B. et al. The clinical journey ofbelantamab mafodotin in relapsed or refractory multiple myeloma: lessons indrug development. Blood Cancer J. 15, 15 (2025).https://doi.org/10.1038/s41408-025-01212-0. REF-24715320. ABBAS, A. K.; LICHTMAN, A. H.; PILLAI, S. Cellular and molecularimmunology. 10. ed. Philadelphia: Elsevier, 2022. REF-30571621. BIRGEGARD, G. et al. Inflammatory functional iron deficiency common inmyelofibrosis, contributes to anaemia and impairs quality of life. EuropeanJournal of Haematology, 2019; 102:235–240. REF-32205922. Al Noumani I; Expert Opinion on Pharmacotherapy; 2026; 27(8), 657–668.REF-331446 Material dirigido ao público geral. Por favor, consulte o seu médico. NP-BR-MMU-WCNT-260004/SETEMBRO DE 2026See omnystudio.com/listener for privacy information.

This week on Sinica, I sit down with Dr. Ruby Wang, whose new book, China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower (Agenda Publishing, out October 31, with a foreword by Kerry Brown), is the explanation general readers have been missing for one of the most consequential and least understood transformations in China today. Ruby is a rare creature in this space: a practicing physician in Britain's NHS, trained in surgery, who worked London's hospital wards through the first wave of COVID; the former head of the UK government's health engagement in China at the British Embassy in Beijing; a former health adviser within the UN system; a onetime medical adviser at AliHealth in Hangzhou; and a Schwarzman Scholar. She now runs the strategy consultancy Lintris Health and writes the excellent China Health Pulse newsletter and podcast, both of which I recommend to anyone trying to follow this space.Anyone who spent time in a Chinese hospital in the late ‘80s or ‘90s — the pre-dawn queues, the ticket scalpers, the cashier's window at every step, the IV drips for a head cold — will find the arc of this book hard to believe. Within living memory, China sent barefoot doctors into the countryside with herbal remedies and antibiotics in army-green satchels; last year, Chinese companies signed something like 186 out-licensing deals worth a disclosed $137 billion, roughly half the global total and close to ten times the 2021 figure, with Pfizer, Bristol-Myers Squibb, AstraZeneca, GSK, and Eli Lilly all buying. Since Ruby gave a terrific interview to my friend Kyle Chan on his High Capacity podcast this spring on the apps, data flows, and clinical AI, I deliberately steered elsewhere: to her family — a deckhand grandfather, a father's crooked splint, a grandmother's transnational hunt for Gleevec — to the four reinforcing conditions she argues made the transformation possible, to the “China is fast because China is loose” shortcut and what's actually behind the speed, to BIOSECURE and its successors, to the AI doctor avatars now fielding millions of inquiries a year, and to the burnout and violence that still bedevil the lives of Chinese clinicians.10:31 – Two family stories from 1970s Zhejiang: a deckhand grandfather and a barefoot doctor's crooked splint15:57 – Four reinforcing conditions, part one: demographic pressure and crisis as catalyst (SARS, melamine, fake vaccines)23:42 – The long view: Healthy China 2030 and why China's health ministers are technocrats27:54 – The cultural inheritance: who signs the consent form, and China's health codes vs. Britain's billion-pound app35:26 – Grandma and Gleevec: a family's transnational hunt for a drug in 200340:17 – The reversal: hǎiguī, copycats to first-in-class, and the tenfold surge in out-licensing42:35 – Is China fast because China is loose? Where China leads (oncology, GLP-1s) and where it lags50:22 – BIOSECURE, COINS, and BINSA: who loses when politics meets pharma55:37 – Digital health in three systems, Ant Afu's AI doctor avatars, and whether the silver generation can keep up1:08:44 – “A lifetime of eating bitterness”: Dr. Wang of Guangzhou, burnout, and yī nàoPaying It ForwardYanzhong Huang, senior fellow for global health at the Council on Foreign Relations and professor at Seton Hall — the go-to voice on the geopolitics of China and health, and Ruby's first port of call.Afra Wang, writer of the Concurrent newsletter — Ruby admires how she reads the cultural currents beneath technology, and finds it endlessly useful to take those insights to the health-tech angle.Olivia Plotnick, Shanghai-based founder of Wai Social — on-the-ground work on branding and consumer behavior across some 30 lower-tier Chinese cities, including health and wellness.RecommendationsRuby: Deep China: The Moral Life of the Person, edited by Arthur Kleinman with Yunxiang Yan, Jing Jun, Sing Lee, and others — what being sick reveals about society and culture in China: psychiatry, caregiving, and how patients and families have changed as the country has. Kleinman's The Soul of Care is also worth your time.Kaiser: Augustus by John Williams — the third of his novels I've recommended on the show, and the National Book Award winner: an epistolary novel of imperial Rome told through a crazy quilt of letters and fragments from family, friends like Agrippa, and poets like Virgil and Horace, each given a completely distinct voice. Quiet campus novel, anti-Western, imperial Rome — the range, and the restraint, are astonishing.Also: Ezra Klein's conversation with Carnegie's Matt Sheehan — a masterclass in clarity on AI safety and the U.S.-China relationship, and the best thing to listen to in the wake of Dario Amodei's “Pacing the Frontier” essay.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

O EVA CAST, podcast do Grupo Brasileiro de Tumores Ginecológicos (EVA), chega ao seu 49º episódio com uma edição especial do Setembro em Flor 2026 dedicada às transformações que estão tornando a oncologia cada vez mais personalizada e ao papel do cuidado humano diante dos avanços tecnológicos.Conduzida pelo jornalista e doutor em Oncologia, Moura Leite Netto, a conversa reúne Andreza Souto, oncologista clínica do Hospital Santa Lúcia/Oncoclínicas, com foco em tumores femininos, oncogenética e oncologia de precisão, mestre em Oncologia, membro da diretoria do Grupo EVA, do comitê de apoio a pacientes do Grupo Gbecam, do comitê científico da Rebrach e do comitê de oncogenética da SBCO; Luciana Landeiro, oncologista clínica do Grupo Oncoclínicas, membro do comitê de ética do Grupo EVA e do comitê de relações institucionais da SBOC e doutora em Ciências pela USP-SP; e Rafael Salim, médico patologista pela Unifesp/EPM, com atuação em ginecopatologia no Einstein Hospital Israelita e no Grupo DASA. O episódio discute o que significa, na prática, personalizar o tratamento dos cânceres ginecológicos. Características da paciente, como idade, condições clínicas, funcionalidade, desejo de preservar a fertilidade e preferências individuais, precisam ser consideradas em conjunto com informações sobre o tumor para definir a estratégia mais adequada para cada caso. A conversa mostra ainda como a patologia passou a fornecer informações cada vez mais detalhadas sobre os tumores. Classificação molecular, características histológicas e biomarcadores podem diferenciar doenças antes agrupadas sob um mesmo diagnóstico e, em determinadas situações, orientar a escolha do tratamento. Entre os temas estão também o uso de novas tecnologias, como cirurgia robótica, radioterapia de alta precisão, terapias-alvo e imunoterapia e a necessidade de avaliar quais pacientes realmente podem se beneficiar de cada estratégia. O episódio aborda ainda as limitações de acesso aos testes moleculares e biomarcadores e os desafios para que a oncologia de precisão não fique restrita aos grandes centros. A inteligência artificial ganha espaço na discussão sobre o presente e o futuro da oncologia. Os convidados explicam como ela pode auxiliar na análise de exames, no processamento de grandes volumes de informações, na integração de dados clínicos, patológicos e moleculares e na identificação de pacientes para estudos clínicos. Ao mesmo tempo, discutem seus limites e reforçam que essas ferramentas devem apoiar (e não substituir) a decisão médica. O episódio também destaca que personalizar o cuidado vai além das características moleculares do tumor. Medos, prioridades, sexualidade, fertilidade, trabalho, independência e outros aspectos da vida da paciente precisam entrar nas decisões. Mesmo diante de exames, algoritmos e tratamentos cada vez mais sofisticados, a escuta, o acompanhamento e a decisão compartilhada permanecem fundamentais.O especial do Setembro em Flor reforça que a tecnologia pode ampliar a capacidade de personalizar o tratamento, mas as decisões continuam sendo construídas entre paciente, médico e equipe de saúde. Ouça, compartilhe e nos ajude a fazer o EVA CAST com seus comentários e sugestões de temas.Siga o EVA nas redes sociais: @gbtumoresginecologicos.Ficha técnicaRealização: Grupo Brasileiro de Tumores Ginecológicos (EVA). Produção: SENSU Consultoria de Comunicação e Banca de ConteúdoRoteiro e apresentação: Moura Leite NettoCaptação e edição de som: J. BenêTema de abertura e encerramento: Gui GrazziotinDireção: Luciana OnckenApoiadores do Setembro em Flor 2026: Libbs, AbbVie, AstraZeneca, GSK e MSD.#setembroemflor #câncer #evacast #cancerginecologico #oncologiadeprecisao #inteligenciaartificial

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. The landscape of these industries is currently experiencing a wave of transformative changes, from strategic corporate relocations and groundbreaking partnerships to pivotal regulatory approvals and promising clinical trial outcomes. Let's begin with a significant corporate strategy shift. Lundbeck has made the decision to relocate its U.S. headquarters to Boston. This move is strategically designed to establish a global innovation hub that enhances its capabilities in neuroscience and artificial intelligence. Boston's burgeoning status as a biotech innovation nexus makes it an attractive destination, offering access to a rich ecosystem of research institutions and technological expertise. Such an environment is crucial for facilitating advancements in neurological research, reflecting the city's growing influence in the biotech world. Turning to regulatory updates, Merck & Co. and Eisai have achieved a notable milestone with FDA approval for their combination therapy of Welireg (belzutifan) and Lenvima (lenvatinib) as a second-line treatment for clear cell renal cell carcinoma. This approval is particularly significant as it marks the introduction of the first HIF-2α inhibitor combined with a tyrosine kinase inhibitor, providing a novel therapeutic approach for patients who have limited options after initial therapies. The combination therapy exemplifies the promise of innovative treatments in oncology, broadening therapeutic landscapes and potentially improving patient outcomes. In business development news, Genentech has partnered with Earendil Labs in a groundbreaking agreement valued at over $1.5 billion to co-develop AI-driven bispecific antibodies for cancer treatment. This collaboration underscores the industry's shift towards harnessing artificial intelligence and machine learning to optimize drug discovery and development processes. By leveraging AI, this partnership aims to accelerate the creation of targeted therapies with enhanced efficacy, highlighting a transformative trend in the industry. Clinical trials continue to yield encouraging results. Johnson & Johnson and Legend Biotech's CAR-T therapy, Carvykti (cilta-cel), has demonstrated a five-year survival benefit in a Phase 2 study for multiple myeloma patients. This milestone emphasizes the long-term efficacy of CAR-T treatments in hematological malignancies, showcasing their potential to significantly extend patient survival rates. In parallel, Regenxbio has reported positive three-year durability data for its gene therapy candidate RGX-314 in non-proliferative diabetic retinopathy, signaling advancements in gene therapy delivery systems that could revolutionize treatments for chronic conditions. Financial activities within the sector also reflect robust investment trends. Sadarx Pharmaceuticals has raised $446 million through an IPO to advance its siRNA and complement-mediated disease pipelines, indicative of sustained investor interest in RNA-based therapeutics. Additionally, Kasvu Therapeutics secured €30 million in Series A funding to propel its neuroplastogen depression candidate KTX-0141 forward, highlighting a growing focus on mental health therapeutics. However, challenges persist amid these advancements. GSK faces scrutiny from the UK self-regulatory body over transparency issues related to vaccine compliance, while Eli Lilly received criticism concerning promotional language about Orforglipron GLP-1 press releases. These incidents underscore the necessity of ongoing regulatory vigilance to maintain industry standards. Overall, these developments reflect a dynamic landscape characterized by strategic realignments, pioneering scientific collaborations, and significant regulatory milestones. The integration of AI into drug development processes and continuous innovation in therapeutic modalities like CAR-T and gene therapies are poised to enhance patient care significantly. As companies navigate complex regulatory landscapes and foster strategic partnerships, these efforts collectively highlight the sector's commitment to addressing unmet medical needs through advanced science and technology. In summary, the pharmaceutical and biotech industries are poised at an exciting juncture where scientific innovation meets strategic business acumen. With each advancement comes the potential not only to enhance patient care but also to redefine healthcare paradigms globally. As these sectors continue to evolve, their contributions promise a future where biotechnology plays an increasingly pivotal role in improving quality of life worldwide. Thank you for tuning into Pharma Daily—your source for vital updates from the frontiers of pharmaceutical and biotech innovation. Stay informed and join us next time as we explore more breakthroughs shaping healthcare's future.Support the show

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Amarah, a high school senior and patient advocate living with EoE and several other chronic illnesses. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [:48] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda. Ryan introduces co-host Holly Knotowicz.   [1:07] Holly introduces today's topic: eosinophilic esophagitis (EoE). EoE is a chronic allergic inflammatory disease of the esophagus.   [1:19] EoE occurs when eosinophils, a type of white blood cell, accumulate in the esophagus in elevated numbers, causing inflammation that can make eating or swallowing difficult or uncomfortable.   [1:30] Holly introduces and welcomes today's guest, Amarah, a high school student who is a patient advocate living with EoE. Welcome, and thanks for joining us.   [1:37] Amarah thanks Holly and Ryan and says she is very excited to be here.   [1:50] Amarah says she is a high school senior. She loves to perform and act. She is also very involved in sports and school activities. She is a cross-country member and a soccer member.   [2:05] Amarah was diagnosed with EoE when she was very young. She has done every treatment you can think of. She has had foods that she was able to eat, and then she couldn't eat them, and then later she could go back to eating them.   [2:19] Amarah says it feels like she has had "millions and millions" of scopes. She has done transnasal scopes and regular scopes.   [2:28] Holly says she and Ryan have been on numerous types of therapy and tried diet elimination. Holly has done the transnasal scope and is excited to hear that Amarah has. Ryan says he feels left out and needs to try a transnasal scope at some point.   [2:52] Holly says we also call it a nonsedated endoscopy. Holly says she loves that Amarah has access to it. Amarah says her state is sparsely populated without those resources, so she flies down to Phoenix, where she used to live, for all of her doctoring.   [3:27] Holly says it's awesome for listeners to know that Arizona is a state where they can get treatment.    [3:47] Amarah says she had a wonderful primary care doctor when she was little. She was having problems around eight months old. At about a year-and-a-half, her primary care doctor suggested she be tested for this "new" disease, EoE. So she got tested.   [4:16] Amarah remembers "not being able to eat anything." That was her normal. She doesn't remember having to take out any foods. The first time she realized she had something more than allergies, she was around 5 or 6 years old.   [4:37] At that time, she realized that something was not the same with other kids who have allergies. What she had was different from a normal allergy.   [4:50] Amarah says she was about 10 or 11 years old when she had a better understanding of what EoE was, inside the esophagus.   [5:16] Ryan compares Amarah's experience to his own, as he was also diagnosed very young. For years, he explained it away as allergies. It's a complicated thing to grasp when you're younger.   [5:45] Amarah is on dupilumab, which is helpful for her eczema, which has resisted topical treatments. Dupilumab also helps with her EoE, so now she is able to have dairy, wheat, and soy. She can't eat them at the same level as people who do not have EoE.   [6:27] Amarah says she prefers a lot of foods that do not have dairy and wheat in them. It's helpful for traveling. She can eat dairy, wheat, and soy, and her scopes come back clean, which is nice.   [6:44] Amarah says that in the past she has done budesonide. She is on PPIs. She had Nissen fundoplication. She also did a drug trial. When she was 12, her EoE got bad. She did a drug trial for an IV drug, and it did not work. She had an adverse reaction.   [7:24] Ryan says he was taking a medication for eosinophilic asthma, which was helping his EoE a little bit, but not a lot. Now that he is taking dupilumab for EoE, that is also helping him with his eosinophilic asthma. Ryan agrees that it is such a game changer.   [7:58] Amarah says she doesn't have other trigger foods, but she is allergic to shellfish due to IgE, not EoE. Peanuts and tree nuts trigger anaphylaxis. Soy, wheat, and dairy are definitely EoE triggers. She used to have to avoid corn but is able to have it now.    [8:38] Amarah says you just know when you eat too much of a food, and your EoE is starting to act up again.    [9:15] Ryan advises listeners to double-check with your care team before you start to introduce triggers back into your diet.   [9:26] Holly says this is so relatable. Holly is significantly older than Ryan and Amarah and didn't get diagnosed until she was older. She loves how Amarah articulated the different paths she has been on as she was growing up.   [9:55] Holly notes that Amarah was at the rise of new treatments that could give her hope to try.   [10:07] Holly asks Amarah to explain to listeners the Nissen fundoplication. Amarah says she had it when she was about four, for her GERD, which is acid reflux. She says some kids with EoE have it done; some do not.   [10:50] Amarah says the sphincter between her stomach and esophagus didn't fully close. The doctor said he had never seen a sphincter look so bad.   [11:04] They did surgery to take a part of the stomach and sew it up so the sphincter closes when food goes down the esophagus, so it stays in the stomach. Amarah says you should not be able to throw up after the surgery, but she still has that ability.   [11:42] Amarah says the surgery can get looser over the years. She has had a couple of tests where the doctors monitor how loose it is.   [11:50] Holly thanks Amarah for articulating what Nissen fundoplication is. Holly is fascinated that Amarah is still able to vomit. That's an important thing to think about with EoE. Holly had the same procedure twice before they knew she had EoE.   [12:53] Amarah says EoE has a lot of layers. It's very complicated. It's very hard to describe it. It takes a lot of extra steps [to manage it].   [13:05] Amarah explains using another diagnosis she has: mild dyslexia. She has to put in more effort and work to do school assignments because she's in advanced classes that require a lot of reading, writing, and spelling.   [13:25] EoE is similar in the way that you have to have the extra steps in order to manage it. She wishes people would know that it's a multi-step process. It's not just one and done.   [13:38] Amarah has been looking at colleges. One of the things she is looking for is whether they have cafeterias she can use. Do they have a disability program she can use and get accommodations for her needs? Do they have a kitchen she can use?   [13:57] Amarah says even though she can have all these different foods, she is still anaphylactic to peanuts and tree nuts. Because EoE can randomly flare up, it's important to her that she has those options.   [14:11] Amarah says EoE is very layered, and she wishes people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager.   [14:34] Ryan says that when he started college, he sat with the university dining hall and the office of disability services to explain his EoE, EoE triggers, and anaphylactic allergies, and to ask if he could eat at the dining hall. They offered the salad bar.   [15:03] The dining hall couldn't accommodate his needs, so he was able to get a dorm with a kitchen so he could prepare his own food.   [15:18] Ryan hopes that 10 years after Ryan started college, the university Amarah chooses will be more understanding of EoE and other allergies.   [15:56] Holly says that as a speech pathologist, she sees people with all diagnoses. There are still schools that don't consider EoE a disability. It's very important to think about accommodations. A patient chose to change schools because of the lack of accommodations.   [16:36] Holly is 42. When she went to school, she didn't know she had EoE, but she had IgE-mediated food allergies, threw up often, and could only eat certain things prepared certain ways. The school said she could eat at one dining hall, but it still wasn't safe.   [17:00] Holly says it has changed in a good way, but in some places, it has not, because some people still don't understand.   [17:11] Holly talks about Amarah avoiding corn and different things. People don't realize you can have an EoE trigger to very different types of foods, not just ones that you are IgE allergic to and need an EpiPen® for. That was key information for Amarah to bring up.   [17:35] Amarah enjoys participating in her school's speech, debate, and drama team. She used EoE as the topic for her informative speech project. Holly watched a video of it, and it was amazing. Holly asks how Amarah came up with the topic.    [19:16] Amarah says that the previous year she had done an informative speech on the history of My Little Pony, of which she is a fan. She decided that for the next year she would do an informative speech on one of the six chronic illnesses she has.   [19:56] Amarah considered which of her illnesses affected her the most. She picked EoE to learn more about it for herself and to explain it better to others, more than just saying she has allergies and can't eat that.   [20:03] Amarah wanted to create something that would be digestible by everyday people for a basic understanding. She had 10 minutes for the speech, so she didn't get into the nitty-gritty of it. She really liked that she got to share it with people.   [20:24] Amarah says she met a judge whose brother had just been diagnosed with EoE. She met another kid who had EoE. He told her he never thought he would see somebody talk about EoE in an informative speech.   [20:50] Amarah says that sharing about EoE was important. She loved doing it.   [20:57] Holly says she loves that Amarah used an outlet she enjoys to share something medically significant in her life.   [21:14] Holly shares how her soccer teammates reacted when she had problems swallowing. She didn't know she had more than food allergies. She and her teammates did a drama, with her as a character always having to vomit. It was releasing to do.   [22:02] Amarah says the informative speech was extremely therapeutic for her. One of her best friends since sixth grade told her, "I had no idea that's what that was." Sharing it with people was very helpful for Amarah and, she hopes, for others.   [22:35] Ryan says it was cool that she was able to connect with others with EoE or with relatives with EoE. It is a rare disease, but people can get the diagnosis more easily these days.   [22:51] Ryan says the speech was only 10 minutes, but Amarah fit so much in those minutes, clearly and concisely. He was very impressed.   [23:22] Amarah says she used 10 sources for her research. APFED was one of her sources. She learned about the number of people who have EoE. It was interesting to learn the difference between the world rate of EoE and the U.S. rate of it.   [24:00] Amarah had not known it was equally common among everybody. Age, gender, and ethnicity do not matter. That was cool to learn.   [24:18] Amarah says it was sad to learn of the lack of public awareness. She learned that the average age of diagnosis was 35 to 50 years old because people aren't aware of it. That was saddening for her.   [25:38] Holly says it can be a missed diagnosis for a time, and it creates more inflammation in certain areas to make things worse. Holly wasn't diagnosed until she was 25. People just thought she was attention-seeking to vomit all the time.   [26:13] Holly says her primary caseload is mostly people aged 18 and up who are newly diagnosed. It's not young kids who are getting diagnosed, like when she worked at a major children's hospital.   [26:39] Holly says Amarah's speech was very informative and well-articulated. It was also dramatic, like a performance, while giving a lot of good information. Holly says it helps people retain information if they're captivated by the presenter.   [27:18] Amarah hopes her peers learned a basic understanding of EoE and some of the ways it works. She covered different treatment plans and food trials, which her peers don't understand until she explains them. That was important to her.   [27:47] Amarah says trying to figure out a way to describe a food trial to somebody who did not know took her a lot of rewrites.   [27:57] Amarah says her last paragraph was about public awareness, why you should care about EoE, and what you should know about it. It's becoming a more prevalent disease.    [28:31] Amarah says that having a basic understanding of EoE creates more acceptance. That's one of the things Amarah hopes to improve in the world.   [28:48] This year, Amarah is writing a Persuasive Essay on why disability should be more prevalent in media because of the level of diversity that it could provide.   [29:03] A lot of people, when Amarah tells them about her disability and chronic illnesses, say, "I am so sorry for you. I feel so bad for you. That must be awful. It must be absolutely horrendous for you."   [29:20] Amarah says these are sometimes the same people who say that they care, but then they do not accept her or her food allergies. They don't accommodate her. They still eat peanuts around her and refuse to wipe their hands.   [29:45] Amarah sees there is a big difference between acknowledging it and accepting it. She used the speech to show people the disability and disease of EoE, some reasons they should know about it, and why they should accept it.   [30:10] Amarah used self-deprecating humor, one of her favorite things to do. Amarah has also done quite a few stand-up comedy acts, which involve self-deprecating humor. She says it's a little bit of a way to cope.   [30:32] Amarah wanted to make something that people would engage in. If she stood up there with a monotone voice for 10 minutes, nobody would remember anything.   [30:41] Amarah says performing like that and having a space where she could show a little bit more of herself that she doesn't normally show to people was not only therapeutic to her, but she hopes that it showed people what EoE is.   [31:04] Holly says, "You just made me cry." It's a hard life lesson when you have chronic illnesses. Holly and Ryan understand that.   [31:20] Holly tells how important it is to her to see disability in the media, whether it's a patient in a medical show that has EoE, or a model in a brand-name ad that uses a cane, as Holly does for a different disability. It hits her in a way that's different.   [31:58] Holly says that seeing and hearing things in the media that are a part of dealing with her disabilities makes her feel included in a way that she never felt with some of her "closest" peers at the time.   [32:12] Ryan says it's wonderful that Amarah is doing this advocacy work through an outlet that she really enjoys and spreading that awareness outside some of these patient advocacy communities. Lack of awareness is an issue.   [32:30] Ryan says people care and want to be accommodating, but if they don't understand it and it's not being presented to them in a way they can parse through and fully understand, it's hard for them to make those steps to be accommodating.   [32:43] Ryan is glad that Amarah is continuing her advocacy work through the essay she is working on in the Speech and Debate Club.   [32:52] Ryan reflects on how great it was to have Amarah join as a patient panelist at the Annual Patient Education Conference, EOS Connection 2026, in Denver, and answer questions for a sizeable audience.   [33:08] Ryan says it was wonderful to see a high school student fielding questions. It was helpful for all the participants in the audience as well.   [33:27] Amarah says she absolutely loved it. It was wonderful. She loved hearing the other panelists' patient stories, and in general, hearing every other kid's experience with EoE. They were all different.   [33:50] Amarah enjoyed sharing her story and having a platform to relate to people. She remembers saying, "You know when your EoE is acting up because you can't eat rice. It starts to get stuck in your throat," and everybody in the audience started nodding.   [34:21] Amarah says having that relatability was helpful. She loves speaking in front of an audience, so that was great, too.   [34:33] It was a different format from the informative speech. Amarah says having to think on her feet meant she had to be more conscious of the words she was going to say. Her informative speech had a written, memorized transcript. Even her hand movements were practiced.   [35:22] Amarah says being able to talk about her biases with EoE and experiences she has had was helpful for her, and she hopes for other people, but very different from her informative speech, which is not supposed to be biased at all. It's not persuasive.   [35:48] Amarah says there were multiple times when she was writing her informative speech that she realized she could not put a sentence in it because it showed bias. She couldn't say, "you shouldn't be mean to people with EoE," for example. That's bias.   [36:21] Amarah says on the patient panel, she was able to do that. A lot of the experiences that she related on the patient panel were things she may have told her parents and some family members, but not anyone in her friend group.   [36:48] Amarah says sharing these experiences and how some of those events had made her feel or had impacted her was something she was not able to show in her informative speech. It was helpful to share her experiences on the patient panel.   [37:26] Ryan says, for our listeners, you can still access the patient panel online. We have on-demand content. We'll link to that in the show notes for this episode.   [37:36] Ryan says people can go back and watch that and hear from you and our other patient panelists. We had a great range of panelists up there. Ryan asks if Amarah learned anything that stuck with her from the panelists or presenters at this conference.   [37:52] Amarah says one of the patient panelists was talking about EoE in the workforce at her job. That was not something Amarah had thought about before. She found it really helpful and something that she will have to think about more in the future.   [38:13] Amarah met a teen who talked about his experiences of having EoE while being on sports buses and sports teams. Amarah found it helpful as she is on sports teams. The student told everyone on his team about his EoE. Amarah found that interesting.   [38:47] It gave Amarah some ideas on how to talk to people on her teams. Amarah just loved meeting all of the people at Eos Connection and learning about their different experiences and how she could improve some of her future experiences.   [39:10] Holly says a key point of the conferences is learning what's coming next in terms of treatment, diagnosis, and all the wonderful things you see health providers doing to support this diagnosis in the world.   [39:29] Holly says when you meet someone else who's going through a very similar experience, there is nothing quite like it. Holly talks about learning from the positive attitudes of other patients she meets at the conferences.   [40:12] Amarah tells EoE patients, "You don't have to tell people if you don't want to." She is a very private person when it comes to her medical stuff, especially during a flare or when there is something new happening.   [40:45] Amarah says she doesn't share it with people until she fully knows what's going on. "You don't have to share it with people if you don't want to."   [40:54] Amarah continues, "Granted, you should probably share your anaphylaxis with your teachers. 'Please don't bring peanuts in the classroom; you will kill me.' But you don't have to get into the nitty-gritty."   [41:06] Amarah continues, "You can just say, 'I have a medical disease. It affects me on a daily basis. I don't want to talk about it.' That is completely OK."   [41:17] Amarah continues, "You do not have to explain anything to somebody. You are not required to. You don't have to. It is your own body. It is your own choice when telling people things."   [41:31] Amarah continues, "It sucks sometimes, and especially kids with EoE, they may have a lot of other chronic illnesses, like me, where everything is combined at once."   [41:48] Amarah continues, "Once something flares up, then the other thing flares up. It sucks sometimes. And that is OK. It is OK that it sucks sometimes. You just have to get through it. You can't wallow in it, but you can acknowledge it."   [42:07] Amarah continues, "If you sit there and 'everything is fine, everything is great,' well, you know, you're actively having a reaction; it's clearly not. And that is something that I still work on today: pretending that everything is fine when it's not."   [42:26] Amarah continues, "You're not going to be perfect. I'm still not perfect. I struggle with talking to people, sharing my experiences, pretending that everything is fine even though I need help, or using self-deprecating humor when it's a serious problem."   [42:52] Amarah continues, "You're not perfect. That's OK.   [42:58] Ryan says that's such a good thing to keep in mind for the patients out there, that it's a journey. There are ups and downs. Finding your comfort level and maturing about the disorder, and keeping in mind that it's not going to be a perfect day every day.   [43:16] Ryan says, Amarah, I'm really glad you were able to join us on this podcast. It was so good to see you at the conference over the summer, as well.   [43:21] I think you're such a wonderful patient advocate. I'm so inspired to see you engaging so much with the community both at APFED and more broadly, speaking about your eosinophilic disorder through these other outlets that are meaningful to you.   [43:39] I know all our listeners are going to appreciate that as well.   [43:44] For our listeners who do want to learn more about eosinophilic disorders, we encourage you to visit apfed.org and check out the links in the show notes.   [43:50] If you're looking to find specialists who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [44:00] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experiences, please check out apfed.org/shareyourstory.   [44:09] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.    [44:20] Ryan thanks Amarah for joining us. This was such a wonderful conversation, and I'm really glad that we were able to have this discussion today.   [44:27] Amarah thanks Ryan and Holly. "I do appreciate it. This was wonderful."   [44:32] Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode. Holly thanks Amarah.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections Eos Connection 2026 Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I love to perform and act. I am also very involved in sports and school activities. I am a cross-country member and a soccer member. I was diagnosed with EoE when I was very young." — Amarah   "It feels like I have had 'millions and millions' of scopes. I have done transnasal scopes and regular scopes." — Amarah   "I remember not being able to eat anything. That was my normal. I don't remember having to take out any foods. The first time I realized I had something more than allergies, I was around 5 or 6 years old." — Amarah   "EoE is very layered, and I wish people would understand that more. It would be more helpful for the level of acceptance and understanding, overall, of having EoE, especially as a teenager." — Amarah   "Having a basic understanding of EoE creates more acceptance. That's one of the things I hope to improve in the world." — Amarah   Guest Bio: Amarah is a high school senior living in Montana. She has EoE and several other chronic illnesses. She loves public speaking and acting. A fun fact about Amarah is that she owns 14 wigs (she loves to create costumes).

In this special crossover episode, Tuesday Night IBS co-founder Jeffrey Roberts, MSEd, BSc, is joined by William D. Chey, MD, Lin Chang, MD, Kate Scarlata, MPH, RDN, LDN, and Amanda Lynett, MS, RDN, at the FOOD is the Main Course conference. ·       How did you manage the diet paradigm shift for managing care in GI conditions? 2:28 ·       How did witnessing the use of multidisciplinary treatment teams change your clinical practice? 15:05 ·       What was it like to manage the unique emotional toll in your career without burning out?  26:13 ·       What advice do you have for residents and fellows in GI? 43:36 ·       What core values do you hope others have learned from your leadership roles? 58:06 We'd love to hear from you! Send your comments/questions to guttalkpodcast@healio.com. Follow us on X @HealioGastro, @sameerkberry and @umfoodoc. For more Tuesday Night IBS, be sure check out TuesdayNightIBS.com and to follow and subscribe to their podcast.   References: ·       Drossman DA. Gastroenterology. 2001;doi:10.1053/gast.2001.28976. ·       Khan S, et al. Nat Rev Gastroenterol Hepatol. 2010;doi:10.1038/nrgastro.2010.137.   Chang reports consulting for Ardelyx, Atmo, Eli Lilly & Co., FoodMarble, GSK, Ironwood Pharmaceuticals and Ono Pharmaceutical; receiving speaking fees from Bausch Health; receiving research grants from AnX Robotica and Ironwood; serving on the Rome Foundation board of directors; and having unvested stock options with FoodMarble, ModifyHealth, PICO Health and Trellus Health. Scarlata reports having stock options with Verve Market, Epicured LLC and Fody Foods and receiving financial support from Ardelyx, Salix pharmaceuticals, Orgain and Activia. Chey, Lynett and Roberts report no relevant financial disclosures.   Chang is professor of medicine and vice chief of the Vatche & Tamar Manoukian Division of Digestive Diseases at David Geffen School of Medicine at UCLA. Lynett is the lead registered dietitian with the division of gastroenterology and hepatology at the University of Michigan and co-director of the Food The Main Course conference. Roberts is a patient advocate and creator of the first website for IBS sufferers. He is the co-founder of Tuesday Night IBS. Scarlata is a U.S.-based dietitian with over 30 years of experience. Her expertise is in gastrointestinal disorders and food intolerance.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CDJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 8, 2027.On Track for Remission in Multiple Myeloma: Modern Off-the-Shelf Choices for Effective and Accessible Care in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CDJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 8, 2027.On Track for Remission in Multiple Myeloma: Modern Off-the-Shelf Choices for Effective and Accessible Care in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily, the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of pivotal advancements and strategic maneuvers shaping the landscape of drug development and patient care. Bayer's Kerendia, known generically as finerenone, has achieved its third FDA approval, this time targeting chronic kidney disease linked with type 1 diabetes. This small molecule mineralocorticoid receptor antagonist plays a critical role in mitigating fibrosis and inflammation—key factors in chronic kidney disease progression. Given the high prevalence of kidney complications in diabetic patients, this approval marks a significant step forward in managing such conditions. Its mechanism offers a novel approach to addressing cardiovascular and metabolic disorders, underscoring its vital role in contemporary therapeutic strategies. In regulatory advancements, AstraZeneca and Daiichi Sankyo's Enhertu has secured approval from NICE for treating HER2-low breast cancer. This marks a significant transition toward precision medicine, allowing the NHS to provide more targeted cancer therapies. Enhertu, an antibody-drug conjugate, exemplifies the shift towards precision oncology by delivering cytotoxic agents directly to cancer cells expressing HER2, thus opening new avenues for personalized treatment strategies. Japan's MHLW has given the green light to GSK's Shingrix in prefilled syringe form for shingles prevention. As a recombinant zoster vaccine enhanced by an adjuvant system, Shingrix represents cutting-edge vaccine technology aimed at strengthening immune responses against the varicella-zoster virus. This approval not only broadens preventative measures but also highlights advancements in vaccine delivery systems. Novo Nordisk's collaboration with Orbis Medicines is another noteworthy development, focusing on oral macrocycle therapies for cardiometabolic conditions—a partnership with potential milestones valued at $1.4 billion. This move aligns with Novo Nordisk's strategic push into small molecule drug discovery to address unmet needs in cardiovascular and metabolic disorders, echoing a broader industry trend towards innovative therapeutic approaches. Meanwhile, Roche has ventured into an agreement with Dualitas Therapeutics to develop bispecific antibody platforms for autoimmune diseases. With an upfront payment of $36.5 million and potential milestone payments reaching $1 billion, this collaboration underscores the burgeoning interest in bispecific antibodies' capacity to target dual antigens simultaneously—offering promising new pathways for treating complex immunological conditions. On the clinical trial front, Roche's Lunsumio has met its Phase 3 primary endpoint, showcasing improved progression-free survival in patients with relapsed or refractory follicular lymphoma. This bispecific antibody exploits the immune system by targeting CD20 on B-cells while engaging CD3 on T-cells, highlighting its potential as an effective option for difficult-to-treat cancers. Conversely, Longeveron's laromestrocel faced setbacks in its Phase 2b trial for hypoplastic left heart syndrome—a reminder of the complexities inherent in developing cell therapies for cardiovascular diseases. Such challenges highlight the critical need for innovative approaches and continued perseverance within clinical development. Regulatory scrutiny remains a pertinent issue as evidenced by the FDA's warning letter to Bausch & Lomb over contamination concerns. This action emphasizes ongoing challenges within ophthalmology manufacturing standards and regulatory compliance—critical aspects that demand rigorous attention to ensure patient safety. These developments collectively reflect an industry characterized by dynamic scientific advancements and strategic collaborations aimed at addressing pressing health challenges through cutting-edge drug development and precision medicine. As companies continue to invest in innovative research and form strategic alliances, these efforts offer significant promise for improving patient outcomes through more effective and targeted therapies. The evolving regulatory landscapes and technological advancements will undoubtedly shape these trends further, offering new opportunities for growth and breakthroughs in patient care. The commitment to overcoming complex challenges remains at the forefront of industry priorities as stakeholders strive to deliver impactful treatments to patients worldwide. Thank you for tuning into Pharma Daily; stay with us as we continue to explore these transformative developments shaping the future of healthcare science.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CDJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 8, 2027.On Track for Remission in Multiple Myeloma: Modern Off-the-Shelf Choices for Effective and Accessible Care in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/CDJ865. CME/MOC/NCPD/AAPA/IPCE credit will be available until September 8, 2027.On Track for Remission in Multiple Myeloma: Modern Off-the-Shelf Choices for Effective and Accessible Care in Relapsed/Refractory Disease In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This week, we report on the Gates Foundation's 2026 Goalkeepers Report, which includes a $1 billion pledge to make AI more inclusive. The funding aims to expand access across health, education, agriculture, and digital equity to directly benefit the global south. We unpack how AI can help lower-income nations tackle critical challenges while ensuring local communities remain central to the process. From the highly anticipated leadership races for the top jobs at the United Nations and World Health Organization, to a critical high-level meeting on pandemic preparedness, we discuss the major themes ahead of UNGA 81, as well as highlight the sessions we are most excited for at Devex Impact House. To dig into these topics, Rumbi Chakamba sits down with Anna Gawel and Catherine Cheney for the latest episode of our weekly podcast series. In the segment of the podcast funded by GSK/ViiV Healthcare, Devex Executive Vice President and Executive Editor Kate Warren speaks with GSK's Chief Global Health Officer, Dr. Harmony Garges. They explore how community-led models, local health worker support, and strategic partnerships are addressing last-mile delivery challenges — from integrating malaria vaccines into primary healthcare in Liberia and Sierra Leone to expanding access to HIV care globally — ensuring much-needed health innovations reach remote and underserved communities. Request to attend Devex Impact House @ UNGA here: https://pages.devex.com/devex-at-unga-81.html

This episode covers:  The role of AI in heart failure and prevention AI advances in interventional cardiology Training cardiologists of the future Host: Fielder Camm Guests: Benjamin Meder, Pim van der Harst, Jozine ter Maaten and Mark Westwood Want to watch that episode? Go to: https://esc365.escardio.org/event/2554 Disclaimer: ESC TV Today is supported by Novartis and Novo Nordisk through independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own. Declarations of interests: Stephan Achenbach, Dan Atar, Yasmina Bououdina, Fielder Camm, Nicolle Kraenkel, Jozine Ter Maaten, Pim Van der Harst and Mark Westwood have declared to have no potential conflicts of interest to report. Carlos Aguiar has adeclared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Benjamin Meder has declared to have potential conflicts of interest to report: Alexion, Alynlam, Amgen, Apple Inc., AstraZeneca, Bayer AG, BNK, Biontech, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cytokinetics, Daiichi Sankyo, Deutsche Gesellschaft für Kardiologie, German Center for Cardiovascular Research, German Research Foundation, Hummingbird Diagnostics, Intellia, Johnson&Johnson, Klaus-Tschira Foundation, Informatics for Life, Leducq Foundation (CASTT), Novartis, Novo Nordisk, Pfizer, SA, Sixt, SMT, Space X, Zoll. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

India supplies a fifth of the world's medicines and invents almost none of them. Venkat Nelabhotla spent three decades inside that industry before co-founding Vyome, and here he explains where drug discovery in India stalls, and why he took a rare disease drug to the Nasdaq instead. Few operators have run a shampoo brand, a vaccine company and a Nasdaq listed biotech. Venkat Nelabhotla took CavinKare from 21 crores to 200 crores, launched India's first recombinant hepatitis B vaccine at Shantha Biotechnics at 300 rupees against the multinationals' 800, and ran Emami as CEO while its market cap went from 200 million dollars to 1.5 billion. Then he co-founded Vyome with a Harvard professor and went after malignant fungating wounds, the open lesions advanced cancer leaves on the skin, for which no FDA approved drug exists anywhere. Speaking with host Akshay Datt, he lays out the rare disease drug development strategy behind a phase two trial that ran on just 15 patients, and his own index of drug discovery in India: if America is 100, China is 40 and India is two or three. It arrives as US tariffs push the Indian pharma industry to think past generics.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant strides and strategic maneuvers reshaping the landscape of healthcare and drug development. Kicking things off, GlaxoSmithKline (GSK) has made headlines with its acquisition of Chimagen Biosciences' trispecific T cell engager technology, targeting multiple myeloma. This move, valued at up to $750 million, highlights GSK's strategic focus on expanding its oncology pipeline through cutting-edge immunotherapeutic approaches. Trispecific T cell engagers are an emerging class of biologics that bind to three different targets simultaneously, effectively arming the immune system to recognize and destroy cancer cells more efficiently. This acquisition not only strengthens GSK's position in the competitive oncology market but also addresses a significant need for more effective multiple myeloma treatments. In parallel, Curium has achieved a notable milestone with the FDA approval of Bexlutry, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This therapy utilizes radioactive isotopes attached to molecules that specifically target cancer cells, delivering radiation directly while minimizing harm to healthy tissue. The approval of Bexlutry is a crucial development in oncologic care, expanding treatment options for patients dealing with complex and heterogeneous tumors. It underscores the growing role of targeted radiotherapies in providing precision medicine solutions. On the financial front, Electra Therapeutics is gearing up for an initial public offering (IPO) to raise $325 million. The proceeds are intended to advance its late-stage clinical trials for severe hemophagocytic lymphohistiocytosis (SHLH), a rare autoimmune condition. This move reflects a broader trend among biotech companies turning to public markets to support niche therapeutic areas with high unmet needs and potential orphan drug status benefits. Turning to clinical advancements, Corbus Pharmaceuticals has reported encouraging Phase 1b data for CRB-913, which employs CB1 inverse agonism in combating obesity. By modulating endocannabinoid activity linked to appetite and energy balance, this approach offers a promising direction for managing metabolic disorders. Simultaneously, CSL Seqirus has shared Phase 3 results showcasing the superior efficacy of its MF59-adjuvanted cell-based quadrivalent influenza vaccine in older adults, highlighting ongoing innovations in vaccine technologies tailored for vulnerable populations. The FDA's regulatory landscape is also evolving with the launch of Operation Trialblazer. This initiative seeks to streamline early-phase U.S. clinical trials through expedited IND application processes, facilitating faster transitions from research to clinical applications and fostering innovation by reducing bureaucratic hurdles. Meanwhile, the FDA is preparing for potential psychedelic medicine approvals, ensuring robust oversight frameworks are in place as these therapies near market availability. Yet, as always in drug development, challenges persist. Novo Nordisk's decision to terminate its GLP-1 obesity drug partnership with Ascendis following unsatisfactory results exemplifies the inherent risks even promising preclinical data can present. Similarly, setbacks faced by Axoltis Pharma and Eli Lilly with their neurological and metabolic candidates reinforce the complexities of translating scientific hypotheses into viable therapies. Sanofi has taken significant strategic steps as well by divesting 20 older medicines and three manufacturing sites to Cheplapharm. This decision aligns with Sanofi's focus on innovation under CEO Paul Hudson's leadership and allows the company to reallocate resources towards groundbreaking therapies. In diagnostic advances, the FDA's approval of Telix's Pixclara marks a breakthrough for brain cancer imaging. Being the first FET-PET imaging drug approved for gliomas, Pixclara could significantly enhance diagnostic accuracy and treatment planning for these challenging tumors. These developments underscore a transformative period where scientific innovation is paired with strategic regulatory adjustments to navigate complex market dynamics. As companies continue adapting to these changes, their ability to innovate while addressing safety and efficacy concerns will be critical in advancing therapeutic frontiers and improving patient outcomes across diverse medical landscapes. As always, we'll be here at Pharma Daily to keep you informed on these pivotal changes shaping our industry's future. Thank you for tuning into today's episode of Pharma Daily. Keep innovating and stay informed!Support the show

Alberto Roldán, profesor de Finanzas de la Universidad Europea, pone el foco sobre Barrat Redrow, GSK y Hugo Boss.

In der heutigen Folge sprechen die Finanzjournalisten Lea Oetjen und Holger Zschäpitz über die krasseste KI-Rotation seit dem DeepSeek-Schock, fette Kursgewinne bei Pharma und neue Fusionsfantasie bei den Börsen-Aktien. Außerdem geht es um Nvidia, Broadcom, Micron, Teradyne, Coherent, Astera Labs, Arm, Siemens Energy, Schneider Electric, Infineon, ASML, Aixtron, BE Semiconductor Industries, SoftBank, Samsung, SK Hynix, Rapid7, Zscaler, CrowdStrike, Palo Alto Networks, Autodesk, Intuit, Adobe, SAP, Dassault Systèmes, Roche, GSK, Deutsche Börse, Euronext, Coca-Cola, PepsiCo, Pfizer, Bristol-Myers Squibb, Schering-Plough, Tesla, Nemetschek, Sartorius, Rational, Fuchs Petrolub, Eurofins, Dürr, Danone, Eli Lilly, Novo Nordisk, Glanbia, Archer-Daniels-Midland, Nestlé, VanEck Sustainable Future of Food ETF (WKN: A3DP9K) und iShares MSCI World Health Care ETF (WKN: A2PHCD). Am 2. Oktober findet unser „Alles auf Aktien“-Summit in Berlin statt. Sichere dir jetzt dein Ticket, um Zugriff auf den Merch-Shop zu bekommen. Mit dem Code „AAAFRIENDS“ sparst du 50 Prozent aufs Ticket – aber nur unter folgendem Link: https://veranstaltung.businessinsider.de/event/financesummit26/summary?rp=c6dc55d6-6f4f-4fb4-b75f-3f3501d84859 Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Hier könnt ihr den AAA-Newsletter abonnieren: https://www.welt.de/newsletter/article232797673/Alles-auf-Aktien-Der-taegliche-Boersen-Newsletter-fuer-WELTplus-Abonnenten.html Und – ganz neu: AAA gibt es jetzt auch auf Instagram: https://www.instagram.com/alles_auf_aktien/ Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Anzeige: Eight Sleep: Der Pod 5 reguliert die Temperatur im Bett automatisch, trackt Schlaf- und Gesundheitswerte ohne Wearable und kann so zu besserem Schlaf beitragen. Mit dem Code ALLESAUFAKTIEN erhaltet ihr auf https://www.eightsleep.com/allesaufaktien bis zu 350 Euro Rabatt. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today's episode delves into some of the latest breakthroughs, regulatory updates, and strategic maneuvers reshaping the landscape of drug development and patient care. Starting with remarkable advancements in drug approvals, Scholar Rock's Isembldy (apitegromab), a monoclonal antibody designed to inhibit myostatin, has secured FDA approval for treating spinal muscular atrophy. This approval came after successful Phase 3 trials and marks a significant milestone in managing neuromuscular diseases. By targeting the myostatin pathway, which regulates muscle growth, Isembldy offers hope for improved motor function in patients suffering from this debilitating condition. Meanwhile, Pharming's Joenja (leniolisib) received an expanded label from the FDA, now approved for pediatric patients aged four and older with activated phosphoinositide 3-kinase delta syndrome, reflecting ongoing efforts to tackle rare autoimmune disorders. Telix Pharmaceuticals has also made strides with the approval of Pixclara (floretyrosine F 18) for PET imaging of glioma, enhancing diagnostic precision for both adult and pediatric brain cancer patients. In clinical trial successes and challenges, GSK and Hansoh Pharmaceutical reported that their antibody-drug conjugate, risvutatug rezetecan, significantly reduced the risk of death in Phase 3 trials for relapsed small-cell lung cancer by 54%. This underscores the potential of targeted therapies in oncology, especially where second-line treatments have been limited. AstraZeneca's Tagrisso (osimertinib), meanwhile, continued to demonstrate its efficacy with a notable reduction in death risk in early-stage EGFR-mutated non-small cell lung cancer at an eight-year follow-up, reinforcing its value as an adjuvant therapy. However, AstraZeneca faced setbacks with camizestrant's Phase 3 trial failing to meet primary endpoints in estrogen receptor-positive breast cancer. A similar challenge arose with Enhertu (trastuzumab deruxtecan) in HER2-mutant non-small cell lung cancer, indicating ongoing difficulties in developing effective combination therapies. Turning to strategic business developments, Johnson & Johnson's decision to divest its orthopedics unit DePuy Synthes to Apollo Equity Management for $20 billion reflects a strategic refocus on core areas like pharmaceuticals and medical devices. Similarly, Novo Nordisk's rebranding as 'Novo' signals an effort to strengthen its competitive stance against Eli Lilly within the GLP-1 agonist market, crucial for managing metabolic disorders such as diabetes. In collaborations and licensing deals aimed at broadening access to healthcare innovations, Bio Usawa's partnership with Axmed is set to enhance access to affordable biologic medicines across Africa, a vital step towards expanding healthcare reach in underserved regions. In oncology research advancements, Owkin has licensed its AI-driven K Pro scientist platform to Servier to accelerate drug discovery through artificial intelligence and machine learning applications. Regulatory challenges continue to shape industry dynamics. The FDA has postponed its decision on Exelixis's Zanzalintinib combined with Roche's Tecentriq for metastatic colorectal cancer until March 2027, reflecting rigorous scrutiny to ensure safety and efficacy. Meanwhile, Cellectis has opted to halt its allogeneic CAR-T programs amid increasing competition from in vivo approaches, showcasing strategic adaptability within the rapidly evolving field of cell therapy. In recent news focusing on mRNA technology and personalized cancer vaccines, Moderna's flu vaccine approval using mRNA technology marks a pivotal moment for this platform after facing skepticism over the years. Furthermore, Moderna and Merck have reported positive Phase 3 results for their personalized mRNA-based cancer vaccine—an advancement positioning them as leaders in personalized cancer immunotherapy following success in melanoma treatment. The sector remains dynamic as companies navigate these complex environments. Breakthroughs such as ivonescimab's success provide optimism for future innovations that could significantly enhance patient care and treatment outcomes across various diseases. The emphasis on mRNA technologies and personalized medicine heralds a new era of targeted therapies poised to redefine standards of care across multiple disease areas. As these initiatives progress, they hold potential not only for improving existing treatment paradigms but also for pioneering new frontiers in healthcare delivery. As these developments unfold, they highlight the industry's dual focus on advancing scientific innovation while navigating complex regulatory landscapes and competitive pressures. The implications are profound: promising enhanced patient outcomes through novel therapies while prompting strategic realignments among key industry players. These initiatives not only aim to improve existing treatment paradigms but also pioneer new frontiers in healthcare delivery.Support the show

In the finale, a new DNA tool, often referred to as genetic genealogy, has finally led investigators to Joseph DeAngelo's doorstep. Paul walks us through the aftermath of finally identifying the Golden State Killer. For the victims, it brings long-awaited answers. For Paul Holes, it brings relief, attention, and a void, much like you'd expect when your 24-year obsession finally comes to an end.  Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠antonfloquet.com⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

On this episode of the IPhO Podcast, we are highlighting how the IPhO Annual Meeting can help students prepare for the industry fellowship process. We are joined by Jenna Brady, PharmD, a first-year Medical Affairs Fellow at GSK in affiliation with the University of North Carolina at Chapel Hill. Jenna shares her experience attending the IPhO Annual Meeting last year and how it helped prepare her for fellowship applications. She discusses how the Annual Meeting provides students with opportunities to connect with current fellows and industry professionals, learn more about various fellowship programs, and gain valuable insights ahead of the application process. The IPhO Annual Meeting will take place September 17–20, 2026. Don't miss this opportunity to connect with industry professionals, expand your network, and prepare yourself for the upcoming fellowship season!

A new kind of DNA analysis changes everything. After learning how genetic genealogy helped identify an unknown victim in a kidnapping case, Paul Holes begins to wonder whether the same method could be used to find the Golden State Killer. Working with a small team, he uses an SNP profile to identify distant relatives and build family trees that may ultimately lead to a name. After decades of dead ends, the case begins to move with astonishing speed - culminating in, at last, the arrest of Joseph D'Angelo. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠antonfloquet.com⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of fascinating updates that are shaping the future of medicine and patient care. First on our agenda is uniQure's ambitious step toward accelerated U.S. marketing approval for AMT-130, a gene therapy targeting Huntington's disease. This move signifies a potential breakthrough in treating rare neurological disorders with genetic roots. The approval of AMT-130 would highlight gene therapy's transformative power, not just for Huntington's disease but also for a broader range of genetic conditions, offering hope to patients where traditional treatments have fallen short. In the realm of oncology, Summit Therapeutics, in collaboration with Akeso, has reported that their bispecific antibody ivonescimab has surpassed Merck's Keytruda in a Phase 3 trial for non-small cell lung cancer. The trial revealed superior overall survival and progression-free survival rates, marking a significant milestone in cancer treatment. Bispecific antibodies like ivonescimab open new avenues for targeting multiple pathways simultaneously, potentially leading to more effective therapies with reduced side effects. Collaboration continues to be a pivotal strategy in drug development. GSK and Hutchmed have formed a licensing agreement for HMPL-A830, an innovative cancer therapy. This partnership involves an upfront payment of $110 million, with the potential to reach $1.3 billion based on performance milestones. Such alliances highlight the importance of strategic partnerships in accelerating therapeutic advancements and expanding the arsenal of available cancer treatments. Moving to regulatory milestones, Samsung Bioepis has secured approval in Japan for its biosimilar ustekinumab, aimed at treating moderate-to-severe Crohn's disease by targeting IL-12/IL-23 pathways. This approval is part of a larger trend towards biosimilars as cost-effective alternatives to biologics, increasing access to essential treatments for autoimmune diseases. In cardiovascular health, Everest Medicines has received China NMPA approval for Cardamyst (etripamil), a self-administered nasal spray for paroxysmal supraventricular tachycardia. The approval underscores innovations in patient-centric drug delivery systems that offer easier administration methods and empower patients to manage their conditions effectively. On the business front, Fortrea has acquired Worldwide Clinical Trials' early-phase division for $45 million. This acquisition aims to bolster Fortrea's clinical research organization platform, reflecting the growing demand for comprehensive clinical pharmacology services that can accelerate drug development timelines. Meanwhile, Pfizer's divestment of its Seagen antibody-drug conjugate PF-08046031 to Medicus Pharma in a deal exceeding $1 billion exemplifies strategic realignments within large pharmaceutical companies. These transactions allow companies to streamline operations and focus on core therapeutic areas where they can make the most impact. Research advancements are also making headlines as Revolution Medicines reports promising Phase 1/2 data for Rasonque (daraxonrasib) in NSCLC patients with KRAS mutations. KRAS has been notoriously difficult to target, so these findings highlight Rasonque's potential as a breakthrough small molecule therapy addressing critical needs in oncology. Despite these strides forward, challenges remain evident. Ultragenyx's GTX-102 did not meet primary or secondary endpoints in its Phase 3 Angelman syndrome study. This setback highlights the complexities involved in developing effective treatments for rare neurological conditions and underscores the inherent risks in high-stakes clinical trials. Turning our attention back to regulatory dynamics, FDA deliberations over Replimune's melanoma treatment revealed nuanced decision-making processes balancing clinical evaluation with strategic considerations. Even amidst internal disagreements, FDA leadership endorsed an accelerated nod for Replimune's therapy—an illustration of how complex these processes can be. In terms of funding innovation, ARPA-H's substantial $125 million investment into personalized RNA-based drug production reflects a commitment to advancing RNA therapeutics despite recent challenges. The initiative could become a catalyst for new approaches in personalized medicine by leveraging RNA technologies to tailor treatments more precisely to individual profiles. Additionally, Roche is making headway in obesity treatment with its UCN2 analog, which shows promise in reducing weight without sacrificing lean muscle mass—an essential factor given obesity's global health implications. This development may introduce new mechanisms of action that could revolutionize existing therapies by overcoming metabolic challenges inherent in obesity treatment. Overall, these developments underscore a dynamic period within the pharmaceutical and biotech sectors characterized by rapid scientific progress and strategic realignments responding to evolving market demands. As companies navigate these changes, their ability to leverage new technologies and refine their strategic focus will be crucial in maintaining competitive advantage and driving future growth—all while aiming to improve patient outcomes globally.Support the show

This episode covers what matters most from ESC Congress 2026:  Heart failure (incl. cardiomyopathies) Primary and secondary prevention ACS & coronary intervention Host: Emer Joyce Guests: Davide Capodanno, Martha Gulati, John McMurray Want to watch that episode? Go to: https://esc365.escardio.org/event/2562   Disclaimer  ESC TV Today is supported by Novartis and Novo Nordisk through an independent funding. The programme has not been influenced in any way by its funding partners. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. All declarations of interest are listed at the end of the episode. The ESC is not liable for any translated content of this video. The English language always prevails. ESC TV Today uses a range of tools and resources (including AI) to support content production. All content is reviewed and approved by the editorial team. Statements and opinions expressed by guest speakers are their own.   Declarations of interests Stephan Achenbach, Yasmina Bououdina and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede, Viatris. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder MyCardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Bristol Myers Squibb, Daiichi Sankyo, Edwards Lifesciences, Novo Nordisk, Sanofi Aventis, Terumo. David Duncker has declared to have potential conflicts of interest to report: lecture honoraria from Abbott, Astra Zeneca, Biotronik, Boehringer Ingelheim, Boston Scientifics, Bristol Meyers Squibb, CVRx, Daiichi Sankyo, Medtronic, Microport, Pfizer, Sanofi, Zoll. Martha Gulati has declared to have potential conflicts of interest to report: Merck-Data Monitoring Committee for lipid lowering product. Emer Joyce has declared to have potential conflicts of interest to report: Alnylam, Bayer, Pfizer, Fire-1. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Felix Mahfoud has declared to have potential conflicts of interest to report: research grants from Deutsche Forschungsgemeinschaft (SFB TRR219), Deutsche Gesellschaft für Kardiologie (DGK), Deutsche Herzstiftung, Ablative Solutions, ReCor Medical. Consulting fees, payment honoraria lectures, presentations, speaker, support travel costs: Ablative Solutions, Astra-Zeneca, Novartis, Inari, Recor Medical, Medtronic, Philips, Merck. John McMurray has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Global Clinical Trial Partners Ltd., WCG Clinical Service, ARMGO Pharmaceuticals, At the Limits Ltd., Hilton Pharmaceuticals, River BioMedics, Novartis, Cytokinetics, Cardurion, Bayer AG, Chugai Pharma UK, Astra Zeneca, AnaCardio, Alnylam, Protherics Medicine Developments Ltd., DalCor Pharmaceuticals, Alkem Metabolics, Canadian Medical and Surgical Knowledge, IMEDIC Pharmaceuticals Micro Labs Ltd., Centrix Healthcare, Eris Lifesciences, Hikma Pharmacueticals, Imagica Health, Intas Pharmaceuticals, J.B. Chemicals & Pharmaceutical, Lupin Pharmaceuticals, Medscape/Heart Org., ProAdWise Communications, Radcliffe Cardiology, Sun Pharmaceuticals, translational medicine academy, Regeneron, MCI India, Emcure Pharmaceuticals, Biohaven Pharmaceuticals, Kirkland & Ellis Int. Ltd., Tangram Therapeutics, Alphasights Ltd., APTA Therapeutics, Zoll Pharmaceuticals, MSN Lab. Ltd., Omicuris PVT Ltd. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Rep. Thomas Massie read 14 names into the record on the House floor, identifying them as Epstein co-conspirators. Among the names: David Copperfield, Tom Pritzker, Leon Black, Frederic Fekkai. Dave Rubin returns LIVE to discuss the latest Epstein releases, the jury in the Lindsay Clancy case entering day 4 of deadlocked deliberations, and GSK's plan to launch a Phase 3 trial for mRNA-based flu vaccines. Then pollster Rich Baris, director of Big Data Poll and host of Inside the Numbers with the People's Pundit, discusses the midterms and the data behind his new book with Joshua Lisec “Burn It Down: What the Polls Say Young Americans Really Want.” Baris says his polling shows a generation that does not want to reform American institutions but replace them, and that commentators calling Gen-Z “more conservative” are reading the numbers wrong. Dave Rubin is the creator and host of The Rubin Report, with over two billion views and more than three million subscribers worldwide. Rubin founded Locals, a subscription-based platform acquired by Rumble in 2021. He is a New York Times bestselling author of Don't Burn This Book and Don't Burn This Country, and launched Copal 22 Reposado Tequila in 2025. Follow at https://x.com/RubinReport Rich Baris is the director of Big Data Poll and host of Inside the Numbers with the People's Pundit. He is the only national and state pollster to correctly forecast Donald J. Trump's 2016 win with 306 electoral votes, and was again the most accurate national pollster of 2024, projecting Trump's 312-vote win. Follow at https://x.com/Peoples_Pundit 「 SUPPORT OUR SPONSORS 」 • BIOPRO - BioPro+® is a natural formula of growth factors and peptides that support how you look, feel & perform. Learn more at ⁠⁠⁠⁠⁠⁠https://drdrew.com/biopro⁠⁠⁠⁠⁠⁠ • FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 ABOUT THE SHOW 」 This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Content Producer • Emily Barsh - ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into the dynamic landscape of the industry, highlighting significant scientific breakthroughs, strategic partnerships, and regulatory updates that are reshaping healthcare as we know it. Novartis recently announced a major milestone with its BTK inhibitor, Rhapsido, which met its Phase 3 clinical trial goals for treating relapsing multiple sclerosis. This success is particularly noteworthy as it comes without any liver safety concerns, a common challenge for this class of drugs. The development of Rhapsido marks a promising advancement in managing neurological disorders, offering new hope for patients dealing with the debilitating effects of multiple sclerosis. However, not all developments are without challenges. Novartis and Bristol Myers Squibb have halted their CAR-T trials due to safety concerns linked to autoimmune conditions like lupus and multiple sclerosis. These pauses highlight the complexities involved in developing CAR-T therapies for non-oncological applications. At the same time, Roche and Simcere Zaiming have joined forces to develop SIM0660, a T-cell engager targeting B-cell diseases. This partnership, involving an initial payment of $75 million and potential milestones up to $1.53 billion, underscores the increasing interest in antibody-based therapies. These treatments leverage the body's immune system, moving towards more targeted modalities for oncology and autoimmune diseases. Meanwhile, drug pricing reforms continue to take center stage as the White House negotiates Most Favored Nation pricing agreements with pharmaceutical giants like Alcon and Astellas Pharma. These agreements aim to make medications more affordable by aligning US drug prices with those in other developed countries. Such policy initiatives reflect growing governmental efforts to address rising healthcare costs and improve access to essential medications. Shifting focus to vaccines, GSK has embarked on a Phase 3 trial for its mRNA-based flu vaccine. This initiative highlights the broader trend of extending mRNA technology beyond COVID-19 vaccines to tackle other infectious diseases. The adaptability and rapid production capabilities of mRNA platforms could revolutionize vaccine development and enhance our response to seasonal influenza. In cardiovascular health, Amgen's Repatha has shown a 20% reduction in mortality risk during a Phase 3 trial focused on primary cardiovascular prevention. This finding reinforces the critical role of PCSK9 inhibitors in lowering cholesterol levels and preventing cardiovascular events for high-risk patients. Similarly, Alumis faced setbacks when its TYK2 inhibitor failed to meet primary endpoints in a Phase 2 study for systemic lupus erythematosus. Despite this, promising subgroup signals suggest potential paths forward. On the regulatory front, the FDA has issued warnings to Alar Pharmaceuticals regarding unapproved promotional claims for its ketamine-based product ALA-3000. Additionally, Boston Scientific has suspended sales of its Imager II angiographic catheters due to manufacturing defects causing serious injuries. Medtronic is recalling its esophageal reflux monitoring capsule over safety issues tied to numerous injuries. These regulatory actions emphasize the critical importance of compliance with safety standards in protecting patient well-being. Industry innovation is further propelled by ongoing fundraising activities supporting cutting-edge research. Companies such as PMV Pharmaceuticals are advancing precision oncology therapies targeting p53 mutations, while Rakovina Therapeutics utilizes AI-powered platforms for cancer drug discovery. These efforts underscore the sector's commitment to addressing complex diseases through technological innovation. The exploration of novel therapeutic modalities continues with Eli Lilly's acquisition of Merida Biosciences for $2.88 billion to target autoimmune diseases by selectively degrading pathogenic autoantibodies. This acquisition aligns with broader trends toward precision medicine solutions aimed at modulating immune responses. In oncology news, Akeso's success with ivonescimab in biliary tract cancer exemplifies the potential of bispecific antibodies beyond initial indications. Meanwhile, Genentech's collaboration with DualityBio aims at overcoming resistance mechanisms in antibody-drug conjugates, promising expanded treatment options for patients resistant to existing therapies. Lastly, Labcorp's introduction of a new hepatitis D test represents a proactive step toward addressing diagnostic gaps in viral infections. Early detection remains crucial for effective disease management and improved patient outcomes. These developments collectively illustrate an industry at the forefront of innovation and strategic adaptation. As companies navigate these evolving landscapes, their focus remains steadfast on improving patient care through groundbreaking therapies while overcoming regulatory hurdles—a testament to their resilience and dedication in pursuing new healthcare frontiers.Support the show

3 Takeaways from my conversation with Deniz Kent, CEO of Prolific Machines: 1. Moonshot thinking starts with a real problem. Deniz saw conflict over resources and asked: what if cells could make everything we need? That question built a company. 2. The best technology has the lowest cost AND highest quality. When those two things align — adoption follows. Every time. 3. Assemble people smarter than you. Deniz conceived the idea. Then got out of the way and hired scientists better than himself. That's leadership.   --- About Deniz Kent, PhD • Co-Founder & CEO, Prolific Machines (Oct 2020–Present). Conceived the core technology, built the leadership team, and secured $90 M+ from top-tier investors including Breakthrough Energy Ventures, In-Q-Tel, Ki Tua Fund, Mayfield. • GSK, Scientist (Sep 2014–Sep 2015). Developed in-vitro monocyte-derived dendritic cell models to investigate tolerogenic receptors. • University of Bristol, Tumour Immunology Researcher (Sep 2014–Sep 2016). Investigated adenosinemediated suppression of CD8⁺ T cells. • UMass Medical School, Visiting Scholar (Jun 2019–Dec 2019). Advanced collaborative research on hepatic cell models. Domain expertise & credentials • Conceived the vision for optogenetic bio- manufacturing and moved to the U.S. to co-found and lead Prolific Machines. • PhD, Centre for Stem Cells & Regenerative Medicine, King's College London ('16–'20). Co-discovered a novel human liver stem cell population (Segal & Kent et al., Nat Comm 2019). Led first high-throughput small-molecule screen on iPSC-derived hepatocytes—identifying 7 novel hits, 2 under patent. • Technical specialties include optogenetics, single-cell RNAseq, iPSC differentiation, AI-driven bioprocess optimization Notable awards & recognitions • Deniz is a member of Founder's Pledge and was appointed to the World Economic Forum's Bioeconomy Initiative. Connect with Jon Dwoskin: Twitter: @jdwoskin Facebook: https://www.facebook.com/jonathan.dwoskin Instagram: https://www.instagram.com/thejondwoskinexperience/ Website: https://jondwoskin.com/LinkedIn: https://www.linkedin.com/in/jondwoskin/ Email: jon@jondwoskin.com Get Jon's Book: The Think Big Movement: Grow your business big. Very Big! Connect with Deniz Kent, PhD: Website: https://www.prolific-machines.com  X: https://x.com/prolificmachine   LinkedIn: https://www.linkedin.com/company/prolific-machines    *E - explicit language may be used in this podcast.

When Paula MacKenzie took over as CEO in 2022, PizzaExpress had been through seven CEOs in eleven years, a billion-pound debt restructuring, 73 restaurant closures, and a pandemic that decimated the casual dining sector. Four years on, she has refurbished three quarters of the estate, grown a loyalty app to four million members, and is targeting 1,000 restaurants worldwide by 2030. In this episode, Sir Richard Harpin, the host of the Business Leader podcast, delves into the numbers, the decisions, and the leadership thinking behind the business turnaround — including why profits fell even as revenue rose, what a refurbishment actually does to a restaurant's economics, and how MacKenzie is expanding PizzaExpress into new formats and new markets.They also cover her career journey — from Ernst & Young auditor to Diageo, GSK, Innocent Drinks and eleven years at KFC — what it takes to go cross-functional and make yourself the obvious CEO candidate, and the leadership lessons she has taken from four years running one of Britain's most scrutinised businesses. And, her advice to the new Chancellor of the Exchequer.In this episode:What PizzaExpress actually looked like when MacKenzie walked in — and the one thing the business needed mostWhy she changed much of the leadership team in her first months, and what a CEO transition coach told her before she even startedHow the loyalty app grew to four million membersThe refurbishment programme — and why underinvested restaurants are delivering 5–10% revenue upliftsThe 1,000 restaurant target — and the new formats, franchise markets and US ambitions behind itHer four-stage playbook for any new CEO: arrive, assimilate, articulate, accelerateWhy she believes you cannot overcommunicate — and how she mystery shops her own restaurantsSubscribe to the Business Leader Podcast for weekly entrepreneur stories from founders and CEOs who've built and scaled great businesses. Join the Business Leader community for coaching, peer to peer forums and exclusive learning events. Sign up to our free weekly newsletter at businessleader.co.uk/newsletters.Business Leader is a membership community for ambitious CEOs and founders of mid-sized UK companies, designed to help them grow with purpose through strategic support, peer-to-peer learning, expert coaching, and high-impact events. Sign up for our Business Leader newsletter here. Hosted on Acast. See acast.com/privacy for more information.

────────────────────────────────────────[00:02:06]Trump's Teleprompter Guy Got Caught Doing Insider Trading — Trump Who Moves Markets by Billions Gets a PassThe staffer made $100K on advance information and got punished; Trump manipulates markets with memes for tens of millions and nobody draws the connection.────────────────────────────────────────[00:03:28]Corporations Are Created by Government in Its Image — That's Why Conservatives Shouldn't Cheer ThemPeople are created by God in his image; corporations by government in its image; they work hand in glove; the left and right both miss this.────────────────────────────────────────[00:18:32]Tesla Autopilot Drove Into Oncoming Trains Multiple Times Before NHTSA Opened a ProbeOne stopped then accelerated into a passing train; another turned onto tracks and was struck; a third slammed a crossing barrier arm; only media attention prompted a patch.────────────────────────────────────────[00:22:19]Tariffs Are Costing Americans $200 Billion a Year — $2,900 More Per Household for the Same Basket of GoodsEvery refund after SCOTUS reversed goes back to corporations; people paid the tariffs with higher prices and got nothing back.────────────────────────────────────────[00:28:05]9/11's 25th Anniversary — Khalid Sheikh Mohammed Has Never Had a Trial; They Don't Want DiscoveryA public trial would allow lawyers to call Mossad witnesses, the dancing Israelis, Netanyahu; due process is for everyone or no one.────────────────────────────────────────[01:03:49]Judge Rules Trump Cannot Deport Non-Citizens for Criticizing Israel — But You Can Be Deported for Criticizing TrumpFreedom of speech is a loser if we're only free to express complimentary views about the government; non-citizens have the same First Amendment rights as citizens.────────────────────────────────────────[01:15:33]Milo Yiannopoulos Deported After Cheering Total ICE Immunity — He Said "I Don't Mean Me" About DeportationOnly deported after he became a critic of Trump; the monster you cheer will eventually come for you.────────────────────────────────────────[01:19:50]Iran War and Tariff Tantrums Are Driving US Farmers Into the Worst Crisis in 40 YearsFertilizer, diesel, and supply chains hit by both simultaneously; food price increases are only beginning — the long train of disruption takes time to arrive.────────────────────────────────────────[01:53:37]Pennsylvania Measles Deaths Are a Lie — Coroner Says Measles Did Not Cause the Newborn's DeathShapiro refuses to release details; GSK got $21 million for vaccine manufacturing in Lancaster County; the fake narrative is meant to overcome local resistance.────────────────────────────────────────[01:56:58]Genes Don't Take Weekends Off But Pediatricians Do — Autism Cases Don't Appear on SundaysMcDowell triplets became severely autistic within two hours of each other after vaccination; perfectly normal beforehand; it is obvious to anyone who hears the story. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-david-knight-show--2653468/support.

────────────────────────────────────────[00:02:06]Trump's Teleprompter Guy Got Caught Doing Insider Trading — Trump Who Moves Markets by Billions Gets a PassThe staffer made $100K on advance information and got punished; Trump manipulates markets with memes for tens of millions and nobody draws the connection.────────────────────────────────────────[00:03:28]Corporations Are Created by Government in Its Image — That's Why Conservatives Shouldn't Cheer ThemPeople are created by God in his image; corporations by government in its image; they work hand in glove; the left and right both miss this.────────────────────────────────────────[00:18:32]Tesla Autopilot Drove Into Oncoming Trains Multiple Times Before NHTSA Opened a ProbeOne stopped then accelerated into a passing train; another turned onto tracks and was struck; a third slammed a crossing barrier arm; only media attention prompted a patch.────────────────────────────────────────[00:22:19]Tariffs Are Costing Americans $200 Billion a Year — $2,900 More Per Household for the Same Basket of GoodsEvery refund after SCOTUS reversed goes back to corporations; people paid the tariffs with higher prices and got nothing back.────────────────────────────────────────[00:28:05]9/11's 25th Anniversary — Khalid Sheikh Mohammed Has Never Had a Trial; They Don't Want DiscoveryA public trial would allow lawyers to call Mossad witnesses, the dancing Israelis, Netanyahu; due process is for everyone or no one.────────────────────────────────────────[01:03:49]Judge Rules Trump Cannot Deport Non-Citizens for Criticizing Israel — But You Can Be Deported for Criticizing TrumpFreedom of speech is a loser if we're only free to express complimentary views about the government; non-citizens have the same First Amendment rights as citizens.────────────────────────────────────────[01:15:33]Milo Yiannopoulos Deported After Cheering Total ICE Immunity — He Said "I Don't Mean Me" About DeportationOnly deported after he became a critic of Trump; the monster you cheer will eventually come for you.────────────────────────────────────────[01:19:50]Iran War and Tariff Tantrums Are Driving US Farmers Into the Worst Crisis in 40 YearsFertilizer, diesel, and supply chains hit by both simultaneously; food price increases are only beginning — the long train of disruption takes time to arrive.────────────────────────────────────────[01:53:37]Pennsylvania Measles Deaths Are a Lie — Coroner Says Measles Did Not Cause the Newborn's DeathShapiro refuses to release details; GSK got $21 million for vaccine manufacturing in Lancaster County; the fake narrative is meant to overcome local resistance.────────────────────────────────────────[01:56:58]Genes Don't Take Weekends Off But Pediatricians Do — Autism Cases Don't Appear on SundaysMcDowell triplets became severely autistic within two hours of each other after vaccination; perfectly normal beforehand; it is obvious to anyone who hears the story. ──────────────────────────────────────── Money should have intrinsic value AND transactional privacy: Go to https://davidknight.gold/ for great deals on physical gold/silver For 10% off Gerald Celente's prescient Trends Journal, go to https://trendsjournal.com/ and enter the code “KNIGHT” For high quality made in America products go to HomeSteadProducts.shop and use promo code “Knight” for 10% off your purchases Find out more about the show and where you can watch it at TheDavidKnightShow.com If you would like to support the show and our family please consider subscribing monthly here: SubscribeStar https://www.subscribestar.com/the-david-knight-show Or you can send a donation throughMail: David Knight POB 994 Kodak, TN 37764Zelle: @DavidKnightShow@protonmail.comCash App at: $davidknightshowBTC to: bc1qkuec29hkuye4xse9unh7nptvu3y9qmv24vanh7Become a supporter of this podcast: https://www.spreaker.com/podcast/the-real-david-knight-show--5282736/support.

Years after stepping away from the case, Paul is pulled back in. The files are still there. The case is still unsolved. And a suspect emerges who seems to fit. Paul Holes spends years chasing this man he believes could be the Golden State Killer, only for DNA to prove him wrong. We learn all about false leads, investigative humility, and the emotional toll of a case that followed Paul into every part of his life. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠antonfloquet.com⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the latest happenings in these dynamic sectors, where scientific advancements, regulatory decisions, and strategic business initiatives are continuously reshaping the landscape of healthcare. Starting with a significant regulatory update, the FDA has granted Capricor Therapeutics a three-month extension to review Phase 3 data for Deramiocel, a promising treatment targeting upper limb functionality in Duchenne Muscular Dystrophy (DMD). This decision underscores not only the complexity of analyzing data in neuromuscular diseases but also highlights the stringent requirements for treatments that aim to improve quality of life for patients with conditions like DMD. In other regulatory news, Johnson & Johnson has expanded the label for its monoclonal antibody IMAAvy (nipocalimab) to treat warm autoimmune hemolytic anemia. This approval is based on compelling Phase 2/3 clinical data and emphasizes the growing role of monoclonal antibodies in targeting autoimmune disorders. These developments offer promising new therapeutic avenues and signify a shift towards more precise treatment options. Moving to infection control, GSK's Hibsago (bepirovirsen) has received approval in Japan for chronic hepatitis B. This antisense oligonucleotide aims for a functional cure by targeting the hepatitis B surface antigen, representing a significant leap forward in infectious disease management. Similarly, Biocon Biologics' biosimilar pegfilgrastim has been approved in Japan for supportive care in neutropenia, crucial for cancer patients undergoing chemotherapy. These approvals highlight the global acceptance of biosimilars as effective and cost-efficient alternatives. The business landscape is also evolving with noteworthy partnerships and acquisitions. Lundbeck and Eversana are expanding their AI-driven commercialization efforts across the U.S., reflecting how advanced technologies are becoming integral to marketing strategies. Meanwhile, McKesson's $2.25 billion acquisition of Precision Medicine Group underscores the strategic focus on oncology and personalized medicine—an area poised for substantial growth. Innovation continues with AC Immune's positive Phase 1 data for ACI-19764, an oral NLRP3 inhibitor targeting chronic inflammatory disorders. This advancement could potentially revolutionize treatments for inflammation-related conditions affecting cardiovascular and neurological health. In ophthalmology, Bausch + Lomb is pushing forward with its combination eye drop therapy into Phase 3 trials for dry eye disease, demonstrating resilience and commitment despite earlier challenges. Shifting focus to obesity treatment, Eli Lilly's launch of Foundayo in the UK presents formidable competition to Novo Nordisk's Wegovy. This move signifies an intensifying race in obesity management, with potential implications for market dynamics and revenue streams. On the financial front, Hansa Biopharma is gearing up for a potential Nasdaq IPO as it awaits FDA decisions on its kidney transplant drug candidates. Amidst this backdrop, Massachusetts has seen a 25% surge in biotech venture funding this year despite challenges faced by startups. Turning to scientific breakthroughs, Jazz Pharmaceuticals has secured FDA approval for its HER2 bispecific antibody Ziihera as a first-line treatment for HER2-positive stomach cancer. This represents not only a new treatment paradigm but also positions Jazz Pharmaceuticals favorably within an estimated $2 billion market potential. In judicial updates, Merck and AstraZeneca's legal challenges against Medicare's drug price negotiation authority have been dismissed. This outcome supports efforts to reduce healthcare costs through negotiated pricing—a move that could reshape pharmaceutical pricing strategies significantly. Meanwhile, Sentivera's licensing deal focused on inflammatory diseases illustrates the financial potential and therapeutic promise of targeting inflammation—a pathway implicated in numerous serious health conditions. Geopolitical dynamics also play a role as concerns arise about China potentially outpacing U.S. companies in biotech innovation. Such developments may influence future policy decisions regarding international collaborations and domestic investments. Finally, scientific exploration continues to push boundaries with advancements such as human brain organoids providing new insights into neurological disorders and potential therapies. Eli Lilly's collaboration on trans-amplifying RNA vaccines further highlights RNA technology's expanding role post-mRNA vaccine success during COVID-19. As these stories unfold, they paint a picture of an industry marked by relentless innovation and strategic foresight aimed at improving patient outcomes globally. From regulatory hurdles to cutting-edge science, each development contributes to a healthcare environment that is increasingly dynamic and poised for future breakthroughs. Stay tuned as we continue to track these important stories impacting the world of pharmaceuticals and biotechnology.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GMB865. CME/AAPA/IPCE credit will be available until August 2, 2027.Vulvovaginal Candidiasis Uncovered: Navigating Accurate Diagnosis and Optimal Treatment in the Age of Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. In the rapidly evolving landscape of pharmaceutical and biotechnology sectors, several significant developments have marked recent progress in drug development, clinical trials, regulatory approvals, and industry partnerships. A landmark partnership between Roche and Hanmi Pharm has been established to develop HM17321, a promising weight loss drug. This collaboration involves a substantial $190 million upfront payment and could reach up to $2.3 billion based on milestone achievements. The high stakes underscore the potential value of addressing obesity through innovative pharmacological interventions, highlighting industry focus on metabolic disorders. Roche's recent $2.5 billion agreement with Hanmi Pharmaceutical emphasizes addressing metabolic disorders through less-explored mechanisms, indicating confidence in its potential to target obesity through novel pathways. Further illustrating industry dynamism, Lundbeck has reported impressive financial performance with a 16% sales growth in the first half of 2026. This growth is driven by the success of Vyepti and Rexulti. Vyepti, an antibody-based therapy for migraine prevention, continues to capture market share due to its efficacy and safety profile. Meanwhile, Rexulti extends Lundbeck's influence in treating major depressive disorder and schizophrenia, solidifying its position in neurological therapies. Significant advancements on the regulatory front have been made for drugs targeting rare diseases and neurological disorders. Spruce Biosciences is advancing toward a fourth-quarter FDA filing for its Sanfilippo syndrome drug following successful manufacturing discussions. This enzyme replacement therapy targets an ultra-rare lysosomal storage disorder with profound neurological impacts on affected children—a vital step forward in addressing unmet medical needs in rare diseases. Moreover, multiple drug approvals across various regions underline regulatory successes. The European Commission has approved Acadia Pharmaceuticals' Daybue (trofinetide) for treating neurobehavioral symptoms in Rett syndrome patients. This approval follows successful Phase 3 trial results and marks an important milestone in managing this severe neurodevelopmental disorder. Similarly, Takeda's Orzeyful (oveporexton), a first-in-class orexin receptor agonist for narcolepsy type 1, has been approved in Japan, emphasizing advancements in targeting orexin deficiency—a key driver of narcolepsy. In oncology developments, Bayer's Hyrnuo (sevabertinib) received approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for HER2-mutant non-small cell lung cancer based on promising Phase 1/2 data. This tyrosine kinase inhibitor represents a novel approach to targeting genetic mutations within cancer cells. Additionally, GC Biopharma's Hunterase has gained approval in India and Taiwan for treating Hunter syndrome (mucopolysaccharidosis type II), utilizing enzyme replacement therapy to address this lysosomal storage disorder affecting multiple organs including the central nervous system. Notably, this therapy demonstrates an ability to cross the blood-brain barrier—a significant technical achievement enhancing treatment efficacy. The regulatory landscape is also evolving with new guidelines such as the UK's MHRA clarifying pathways for microbiome-based medicinal products. These developments underscore the growing interest in microbiome therapies as promising approaches to treating infectious diseases. Amidst these advancements, challenges persist as seen with Regenxbio facing a 22% share drop following an FDA clinical hold on its Hunter syndrome gene therapy RGX-121 due to spine MRI findings. This situation highlights inherent risks associated with cutting-edge gene therapies despite their groundbreaking potential. Overall, these scientific developments and regulatory updates illustrate a vibrant pharmaceutical and biotech industry focused on innovative treatments addressing complex diseases. This momentum promises enhanced patient care while signifying a robust pipeline of therapeutic options poised to transform disease management paradigms across multiple domains. The industry continues to witness significant scientific advancements and regulatory shifts. GlaxoSmithKline's (GSK) achievement of securing the world's first regulatory approval for a hepatitis B vaccine in Japan underscores GSK's leadership in infectious disease prevention—a critical advancement in global public health efforts. Moreover, collaboration between Roche and Eli Lilly culminated in FDA approval for an innovative Alzheimer's biomarker blood test. This diagnostic tool offers a groundbreaking development in Alzheimer's disease management by providing a less invasive method for early detection and monitoring—crucial for improving patient outcomes and tailoring therapeutic interventions. On strategic corporate fronts, Daiichi Sankyo is enhancing its oncology portfolio by promoting Ken Keller to head a new commercialization unit aimed at becoming a top-five oncology player by 2035. This reflects broader industry trends toward specialized therapies offering substantial clinical benefits. Cell therapy sector dynamics are also evident as Cellares' CEO plans operational resizing after losing a significant manufacturing client—a reflection of broader industry dynamics where scaling innovative therapies like automated cell therapy requires balancing operational capabilities with market demands. Berry Street's merger with Healthify aims to expand AI-driven metabolic care by integrating Healthify's AI technology with Berry Street's clinical network—aligning trends toward personalized medicine and digital health integration. On the regulatory front, Spruce Biosciences progresses towards filing for FDA approval of its ultra-rare disease drug candidate emphasizes commitment to developing treatments despite complex pathways promising significant impact for underserved populations. Lastly, TME Pharma remains optimistic about its brain cancer drug nearing partnership conclusions reflecting confidence despite competitive pressures—highlighting key scientific advancements shaping pharmaceutical landscapes emphasizing innovative therapies' focus on improving patient care outcomes through enhanced diagnostics novel therapeutics comprehensive healthcare solutions. Recent developments highlight significant scientific advancements poised to influence patient care trajectories as Capricor Therapeutics received a three-month extension from FDA reviewing additional data refined indication Duchenne muscular dystrophy therapy candidate deramiocel set November 22 action date underscoring FDA commitment thorough evaluation processes providing potential new treatment option pending approval. In contrast, Regenxbio faces FDA hold RGX-121 gene therapy candidate aimed at Hunter syndrome due to small nodules cystic masses spines patients registrational trial highlighting ongoing challenges gene therapy rigorous safety assessments complexities developing advanced genetic treatments. With Roche entering substantial agreement Hanmi Pharmaceutical access investigational obesity drug HM17321 next-generation asset aims induce weight loss enhance lean mass positioning potentially transformative therapy burgeoning weight management market reflecting growing interest competition obesity treatments strategic focus expanding metabolic disorder portfolio. Regulatory business maneuvers paralleled broader industry trends including shifts manufacturing strategies essential advanced therapies innovative approaches underscored recent discussions vivo delivery systems reshaping viral vector production improving efficiency scalability potentially lowering costs accelerating time-to-market further highlighting rigorous safety standards governing clinical research drug development processes landscape therapeutic development continues evolve companies like Novo Nordisk trialing lower maintenance doses oral Wegovy obesity treatment gained significant market traction initiatives reflect ongoing efforts optimize dosing regimens enhance patient compliance outcomes collectively underscore dynamic period pharmaceutical biotech sectors characterized scientific innovation strategic investments regulatory scrutiny implications profound patient care new therapies promise address unmet medical needs navigating complex environments adapt changes influence future drug development strategies therapeutic landscapes significantly events signal not only challenges opportunities companies strive bring novel treatments market safely effectively ultimately aiming improve patient outcomes various disease areas poised intersection technological innovation oversight driving advancements hold potential enhance care expand possibilities.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GMB865. CME/AAPA/IPCE credit will be available until August 2, 2027.Vulvovaginal Candidiasis Uncovered: Navigating Accurate Diagnosis and Optimal Treatment in the Age of Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/GMB865. CME/AAPA/IPCE credit will be available until August 2, 2027.Vulvovaginal Candidiasis Uncovered: Navigating Accurate Diagnosis and Optimal Treatment in the Age of Resistance In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis educational activity is supported by an independent medical education grant from GSK.Disclosure information is available at the beginning of the video presentation.

Co-hosts Ryan Piansky, a patient advocate living with eosinophilic esophagitis (EoE) and eosinophilic asthma, and Holly Knotowicz, a speech-language pathologist living with EoE who serves on APFED's Health Science Advisory Council, interview Timothy Buckey, MD, MBE, an allergy and immunology attending physician with a joint faculty position at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. Disclaimer: The information provided in this podcast is designed to support, not replace, the relationship between listeners and their healthcare providers. Opinions, information, and recommendations shared in this podcast are not a substitute for medical advice. Decisions related to medical care should be made with your healthcare provider. Opinions and views of guests and co-hosts are their own.   Key Takeaways: [00:48] Co-host Ryan Piansky introduces this episode, brought to you thanks to the support of APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   [1:04] Ryan introduces co-host Holly Knotowicz. Ryan just returned from APFED's 24th Annual EOS Connection Patient Education Conference. It was a wonderful time. Listeners can still check out the resources on demand online.   [1:26] Ryan mentions that a handful of people came up to him at the conference to say how much they appreciate the Real Talk podcast. It was wonderful to hear how impactful the podcast has been for them.   [1:53] Holly introduces today's topic: how parents and caregivers can help children and teens with eosinophilic disorders build the skills and confidence they need to manage their health as they grow and navigate transitions from pediatric to adult care teams.   [2:06] Holly introduces and welcomes today's guest, Dr. Timothy Buckey, an allergist and immunologist at the University of Pennsylvania and the Children's Hospital of Philadelphia.   [2:14] Dr. Buckey's research interests include eosinophilic esophagitis, food allergy, medical ethics, and improving access to medical care for vulnerable populations.   [2:24] Dr. Buckey thanks Ryan and Holly for having him on the program. He's a long-time listener and is looking forward to the conversation on this important topic.   [2:32] Holly comments on Dr. Buckey working with children and adults. Dr. Buckey says he sees patients of all ages, from a few days old at the Children's Hospital through the end of life at the adult hospital. He loves that there's no patient he cannot see.   [3:10] Dr. Buckey says, in addition to seeing patients as an allergist/immunologist, he is also a medical ethicist or bioethicist. He is trained in medical ethics, and he utilizes that approach in shared decision-making, trying to understand his patients' goals and values for their health, and making a plan that works for them.   [3:31] Holly says her allergist/immunologist at Massachusetts General also sees teens and adults.    [3:53] Dr. Buckey says a special aspect of the relationship he has with his patients is that he has been in a fairly similar position, as someone who has dealt with many different allergic or atopic conditions for his whole life.   [4:08] Dr. Buckey says his conditions started with asthma as a young child, which he still manages, allergic rhinitis, and environmental allergies. He has been on allergy shots. He deals with atopic dermatitis, or eczema. He has seen an allergist/immunologist his whole life. It feels like full circle to be one now.   [4:29] Ryan feels like it's easier from a patient perspective if your physician gets it and can understand what you're going through.   [4:41] Ryan says that eosinophilic disorders generally require lifelong management, especially when diagnosed in children. Over time, a patient may need to transition from being treated by a pediatric care team to an adult care team.   [4:57] Ryan says that Dr. Buckey, through his work with the University of Pennsylvania, provides a lot of support for young adults going through that transition. Ryan asks Dr. Buckey to explain the importance of transition of care.   [5:14] Dr. Buckey breaks down the term into its two words: transition and care.   [5:24] Transition of care is a process in which we are shifting from a pediatric health model, in which a parent or guardian is the primary historian, or person managing the patient's care, to one in which the patient becomes the primary point of contact.   [5:49] Dr. Buckey says that during this process, our overarching goal is for an individual to begin to develop ownership of their health so that they can take care of their medications, schedule appointments, and know their bodies.   [6:05] Dr. Buckey says the second part is care. Not only medical care, but it is a period of life of going through a lot of personal growth. Dr. Buckey's goal is for patients to know themselves and learn to support themselves as independent individuals.   [6:30] Holly appreciates that Dr. Buckey talked about the transition at that age when there are so many things going on with becoming an adult.   [6:40] Holly says when she worked at the Children's Hospital of Colorado, we thought about this a lot.   [7:00] Holly said that when she interacted with patients, she tried to look at them, even if they were little. If they were three or four, she asked them what their favorite foods were.   [7:17] Holly says she was trying, as young as possible, to have them feel that they have some say and control over their health, and they can start developing how to be a historian of their medical journey.   [7:36] Dr. Buckey says every person matures or develops at different times. Having a strict age cutoff may ignore the unique aspects of each person and their history. Dr. Buckey generally begins that conversation in the teenage years through the early 20s.   [8:02] Dr. Buckey says that with some kids, he will introduce the idea earlier than a teenager, based on how much they understand about their health. As they start to switch to adult care, he emphasizes that the transition process is not over at their first adult visit.   [8:24] Dr. Buckey says it takes additional visits for that person to understand themselves, to know how to request a refill of their medication, to know how to make the appointment, and to know how to contact Dr. Buckey if they have questions.    [8:38] Dr. Buckey says it is a continual process, and it doesn't just stop at that first visit with an adult doctor.   [8:45] Holly agrees that people reach maturity at different ages. Holly remembers that when she was in college, she asked her mom to schedule her dentist and doctor appointments.    [9:17] Dr. Buckey says it's overwhelming and it can be quite scary. It takes a team.   [9:30] Holly notes there are age ranges on the Healthcare Transition Timeline Toolkit for what the provider should be doing to help the patient get ready for transition, and what the caregiver and the patient should be doing. She invites listeners to check it out at eoscare.apfed.org.   [9:45] Holly asks about ages when a child would meet alone with their physician for part of the appointment to talk about things they don't want to say in front of their parent.   [10:18] Dr. Buckey says it depends on age and individual factors. He says he has met some very mature 10-year-olds and some not-as-mature 17-year-olds.   [10:38] Dr. Buckey says he understands how it might be nerve-wracking for parents to ask them to step out, but it is an important part of that person starting to know their own body.   [10:50] Dr. Buckey says if he's seeing an individual with asthma, he will have the parents step out briefly from the clinic room so he can have a conversation about possible triggers they may not be comfortable talking to their parents about, such as vaping or cigarette use, and if they have tried them or friends have tried them.   [11:20] Dr. Buckey says they will discuss that, and that's not something they always feel comfortable sharing with their parents because they feel like they may be disappointing them. The doctor needs to know it to keep them healthy.   [11:44] Holly says in her practice, a lot of teenagers will ask to meet with her if they have IgE-mediated food allergies on top of eosinophilic-related disease.   [11:51] They want to know if it's safe to kiss a person if they've eaten this or what to do to protect themselves. If they get this symptom, what should they do? They feel comfortable asking Holly. She's trying to coach them to feel confident in their bodies.   [12:22] Ryan comments that he's gone through the transition of care process relatively recently. The conversation has touched on so many things he remembers from the last 10 years of trying to transition.   [12:28] Even before that, at eight or nine, when the doctor asked what medications Ryan was on, his mother looked at him and said, You should know this; you take them every day. What medications are you on?   [12:43] Ryan says that was super helpful to him, as a young patient, that his parents supported him in making sure he was aware of his health, his treatment options, and was able to guide his own medical appointments, with supervision.   [12:57] Ryan had had no idea that he was choking on food or taking extra time to chew. It felt normal, so it was helpful to have a caregiver in the office. His caregiver would say it takes him half an hour to have a handful of crackers. That should not be happening.   [13:20] Ryan asked about caregivers helping with appointment management and prescription management. Until recently, Ryan's parents helped him.    [13:50] Ryan says, even into your 20s, that transition process is still happening. Ryan asks Dr. Buckey for advice on teens and young adults making their own appointments and dealing with healthcare systems.   [14:04] Dr. Buckey says it's difficult to navigate our healthcare system. There are questions about insurance and what is in-network vs. out-of-network. How do you get prescriptions filled? What's covered? Cost? So it's complicated.   [14:21] Dr. Buckey emphasizes that when we're talking about this transition process, sometimes a part can get misconstrued: that we don't want parents or caregivers involved. We do.   [14:35] Dr. Buckey says his goal is for people to have the community, however they define that, to still be a part of their healthcare. What he is aiming for with this transition is that the individual starts to take control of their own health.   [14:50] If making appointments is something they still need some help from their parents, that is them recognizing what they need. [14:57] If they want to come to the visit but have Mom or Dad or their significant other on the phone, because that is the support that they need, then absolutely do that.    [15:08] Dr. Buckey says, as we are generally switching over, at 18 into our early 20s, recognizing the support you need is an important part of knowing your own body.   [15:20] Holly says that's an important stage, and she got there later. She needed help when she was younger; then, in her teens, she said, "No, I've got it." Now, in her 40s, she would like some help again.   [15:37] Holly says it's OK to ask for help when you're feeling overwhelmed, and you can't navigate all these chronic diseases on your own.   [15:42] Ryan says this is a topic we're both passionate about. At APFED, we see younger patients stop seeing their care team when they get to their college years.   [15:54] Ryan says part of it is they get busy and are not able to engage with the patient advocacy community as much, and part of it is they drop out of care. It's important to have caregivers or your community to support you through that process.   [16:07] Ryan says, whatever it takes to stay in care and make sure you're healthy is super important.   [16:14] Ryan brings up legal age cutoffs. In his 20s, he has access to his medical records; his parents don't. He still wants their take on some stuff. After he gets an endoscopy, he pulls up MyChart to show his parents his results.   [16:38] Dr. Buckey says once we turn 18, we are legally adults. At that point, the patient is the owner of their health and their information. They have to provide access to their parents to be able to see it. That can be done in several different ways.   [16:55] If you have an electronic health record, sometimes you can add a proxy, or you can just pull up the results and choose to show your parents.   [17:05] Dr. Buckey says if he is seeing an 18-, 19-, or 20-year-old at the Children's Hospital, he will tell them that once they turn 18, he only communicates results to them.   [17:16] Of course, they can have their parents, caregiver, or significant other present. That is their choice to invite them into that conversation. That is very helpful for many people.   [17:30] Dr. Buckey is a proxy for his parents. Holly is also a proxy for her parents.   [17:41] Holly says that having somebody who is in your corner to talk about your results with and talk about the next stages of treatment is always important because it can be overwhelming.   [17:51] Dr. Buckey gives kudos to pediatric providers. They are so wonderful, and they build such a great relationship that it makes it hard for us to want to leave.   [18:03] When Dr. Buckey was at the point of applying to medical school, his pediatrician told him they needed to have him see an adult doctor. He was reluctant to transition. His pediatrician inspired Dr. Buckey to go into medicine.   [18:25] Ryan says it can be a hard transition, with so much else going on that you want to stay in that familiar environment.   [18:31] Ryan shares how he recently dealt with transitioning insurance plans.   [18:55] Dr. Buckey says the general rule is that you can stay on your parents' health insurance until you are 26. There are caveats for individual persons and individual insurance plans.   [19:05] Some people start working and may get health insurance through their job, so you may have your own health insurance at 18 and no longer be on your parents' insurance.   [19:16] When you're 16 or 17, it's an important time to talk to your parents, or whoever's insurance you are on, about what's going to happen when you turn 18.   [19:26] Ryan says it's specific to each medical plan. He says when he went to college, he was offered a student health insurance plan, but his specialty medications, like biologics, were not covered, only hospitalizations.   [20:00] Ryan says it's always good to double-check what your plan options are and what those plans cover, to make sure that you're able to maintain the care you need.   [20:12] Holly says that something really helpful is to sit down with the family and help them identify an adult care team that will fit them best as they transition.   [20:33] Dr. Buckey says sitting down and having that conversation is an important part of the visit. Talk to patients about where they will live. If you're living away at college or moving away for a job, what geographic area are you moving to?   [20:53] If you're going to be on a different coast or city, do you want to switch your care over to that area? Or do you want to keep your care in the area where your parents live and come back during your breaks and see your physician?   [21:09] Dr. Buckey says it's also important to have a local provider to go to if something comes up. Talk to your pediatric provider about whether they know adult clinicians who care for the condition that you have in the area where you will be living.   [21:30] Dr. Buckey says another important thing to think about is,  when we are in pediatric care, we are often follow-up or return patients. Visits may be of a different duration. Sometimes it's easier to schedule a follow-up visit than a new patient visit.   [21:48] Planning that new patient visit in your new area, sometimes weeks or months ahead, is an important part of this transition process to ensure that there are no gaps in the care you're going to be having.   [22:08] Holly mentions the APFED Specialist Finder on the APFED website. It's a tool for when you are not part of a multidisciplinary setting or wherever you're going, no one knows who they would recommend in that part of the country.   [22:25] There are a lot of good people listed on the APFED Specialist Finder if you are going to be moving somewhere else or getting your care in another place. Dr. Buckey proudly shared that he is on that Specialist Finder. So is Holly.   [22:51] Ryan recently moved to California, and he is trying to find care teams there that specialize in EoE.   [23:12] Ryan asks if patients transitioning to a new doctor typically need a referral from their existing physician, or do you chat with your insurance company first to help find new care teams?   [23:25] Dr. Buckey says some insurance policies do require a referral for each visit you are going to have with your provider. For many policies, you can look online to see who is in-network vs. out-of-network.   [23:52] Sometimes there are different costs to see someone who is in-network vs. out-of-network. The differences can be dramatic. Discuss it with your physician or clinician, but also with your insurance company.   [24:13] Dr. Buckey says make sure there's no lapse in care. We don't want someone to go without their medication. If you're no longer seeing your pediatric provider, make plans to see an adult provider who can continue your prescriptions.   [24:45] Ryan says we see a lot of patients who have an EGID and also other conditions. We see a lot of comorbidities within our community. We have multiple things going on, which can make this transition process especially complicated.   [25:15] Dr. Buckey says many people are experiencing different things and may need to see more than one clinician. They probably also have a primary care doctor. They are going to have to switch from each of those clinicians to an adult provider.   [25:38] That transition takes time and effort. It can sometimes be a long wait. Beginning that process early will only set you up for success. Dr. Buckey says different health systems will accept different insurances.   [26:01] Dr. Buckey says sometimes for specialty medicines, when you switch health systems, the specialty medication may be provided by a different specialty pharmacy than it was when you were seeing a pediatric healthcare team.   [26:13] How you schedule appointments, how you speak to someone if you're having new symptoms, all changes as you're switching to adult care. Dr. Buckey says because this is complicated, we do worry that sometimes things can get lost during the transition.   [26:37] Planning will only set you up for success, so that nothing gets missed in the switchover process; you have no lapse in medications or procedures that you need, and you can continue to see the clinicians you need to keep you healthy for your best life.   [27:03] Holly has learned from her healthcare and working in different hospitals to ask, before picking a specialist, what electronic medical records (EMR) the practice uses. Some can communicate with each other, and it makes the transition smoother.   [27:25] Holly says some places have EMRs that don't communicate with other places, and that makes sharing information tricky. Holly has experience dealing with EMRs that do not talk to each other at all.   [28:05] Dr. Buckey says if you use an EMR that communicates with others, your care can easily be accessed at different institutions. Dr. Buckey explains how that helps make the transition smooth if transferring to adult care or switching healthcare systems.   [28:56] Dr. Buckey says things you need for a helpful transition are to know your medical history, your diagnoses and how they were made, your current medications and dosing, and medications or therapies you tried before that weren't successful for you.   [29:31] Dr. Buckey says, as we approach the era of precision medicine where we are treating each person in a different way, knowing what did or did not work for you is so helpful for your clinician so they can continue to help you feel good.   [29:49] Holly suggests a role-play. For example, if she's going to see Dr. Buckey with her records from Maine, which do not communicate with his EMR. What should she physically bring to the visit?   [30:23] Dr. Buckey says to know what health conditions she is being treated for. In Holly's case, they will talk about asthma and EoE.   [30:33] Dr. Buckey would like to know if Holly has ever been hospitalized for asthma, what inhalers she takes, what inhalers she tried before, and if she is on any biologic medicines, the doses and the frequency, and what she tried in the past.   [30:53] Dr. Buckey would ask if she's ever had breathing tests, called spirometry or pulmonary function tests.   [30:58] Having paper copies is wonderful. You can bring them in, and he will review them at the visit. Dr. Buckey always appreciates it when patients send them to him ahead of time, so he can review them and prepare for a successful first visit for both of them.   [31:18] Dr. Buckey says if we're talking about EoE, he will ask when the diagnosis was made, what symptoms led her or her parents to do that first endoscopy or see an allergist, immunologist, or gastroenterologist, when the most recent endoscopy was, and what medications she was on when she had her different endoscopies.   [31:40] Dr. Buckey says usually clinicians are keeping track of this, so Holly could ask them for copies of procedures she has had, the last two or three office visits, which are usually pretty comprehensive, and a list of any medications Holly takes.   [32:00] Holly appreciates having the ability to send paper records in advance. When Holly sets an appointment, she will fax Dr. Buckey some of her tests and important facts to look at before her appointment.   [32:20] Holly says some places won't look at the reports in advance, so she brings a bullet list with her of all the things Dr. Buckey listed for them to look at when she checks in to the appointment.   [32:39] Dr. Buckey responds that healthcare is very busy and some clinicians don't have the time to look at reports ahead of the visit, but can take five or ten minutes to look at them at the start of the visit to be successful and have a comprehensive visit.   [32:59] Ryan appreciates Holly's point to bring a bulleted list to the visit. Ryan is grateful that his parents kept his records organized throughout his life. For any caregivers listening, set your patients up for success by keeping track of these things over time.   [33:24] Ryan has a one-page summary he gives to all new providers of all his hospitalizations over the last 20 years, the medications he has been on, with date ranges, his diagnoses with dates, and different procedures and endoscopies.   [33:46] Ryan says that one-page summary is in 6-point font to squish it down to one page. It's helpful to have all that information organized together.   [33:55] Ryan invites caregivers: If you have a young patient and you're starting to think about the transition process, start keeping track of all that if you haven't before.   [34:03] Dr. Buckey says our health can be complicated. We can have periods when we're feeling great and periods when we're having more symptoms. Having it written down is an easy way to keep track so things don't get forgotten or lost.   [34:22] Dr. Buckey often says he appreciates when patients come in with that sort of list of their history because it shows how invested you are in your health and keeping yourself healthy. It's a wonderful way that you can be proactive.   [34:40] Ryan says it can feel like a big undertaking if you start now and you're in your 20s. Whenever you can start keeping track of how you're feeling and why, what treatment and symptoms you're having, it's good to have more information than less.   [34:58] Dr. Buckey says there's never a period when it's too late. If you are in your 30s or 40s and just starting out, it's very helpful. The provider can prompt you with questions that will help you recall things you had in the past and add them to the document.   [35:21] Ryan says it's a very collaborative process. Discuss it with your clinician, who may point out symptoms you should note.   [35:40] Ryan asks, when you are transitioning from pediatric to adult care, is it typical for an adult care provider to call a pediatric care provider with questions? Dr. Buckey says in his system, doctors have those conversations, which is a great asset to patients.   [36:33] Dr. Buckey says, for example, if I were not their pediatric allergist, but I would become their adult allergist, I would reach out to their pediatric allergist and ask details about their history. I would also reach out to their dermatologist and gastroenterologist.   [36:59] It's helpful to ask each other questions, know things to look out for, or things in a person's history that might be helpful as therapies and medications continue to advance that might be a good fit. It helps us to have a good comprehensive plan in place.   [37:26] Dr. Buckey says talking to each other helps to provide good longitudinal care.    [37:39] Ryan asks about having procedures and allergy testing in a pediatric setting and switching to a new provider. Do adult providers typically want to repeat testing?   [38:04] Dr. Buckey says it will depend on each person, when they were performed, and what was performed. If Dr. Buckey is seeing someone for food allergies, was skin or blood testing done last year or 10 or 20 years ago? Last year is pretty current. If it was 20 years ago and you're 22, your body is very different from when you were two.   [38:40] Dr. Buckey says if you have asthma and you had a breathing test two weeks ago, that's very recent. If you have not had a breathing test done in 10 years, I probably would repeat it on your first or second visit.   [38:56] Dr. Buckey says, for endoscopies, if you have EoE of another EGID, it would depend on timing. Was this done recently or in the remote past? Was it done on the current regimen you are on? Was it done on a different regimen?   [39:14] Dr. Buckey says I'm going to ask you if you're having any changes in symptoms recently. If anything has changed how you're feeling, it's probably going to prompt me to do a new set of testing and not just rely on the ones you had before.   [39:31] Dr. Buckey says, if you could bring the previous tests to me, I can compare. I can see what your endoscopy looks like now vs. two years ago. It's helpful to have that baseline to compare to.   [39:48] Dr. Buckey adds that knowing how you're feeling, or what's been done before, or your medical history, helps clinicians to take care of you as best we can.   [40:15] Holly says this is such a needed conversation. It will be helpful for our listeners, both practicing physicians and patients.   [40:37] Holly asks what advice Dr. Buckey gives for navigating challenges during the transition of care.   [40:51] Dr. Buckey says for every new EoE patient visit, he shares a link to the APFED website because there are such wonderful resources and references there. He explains to them what APFED is, and he provides resources to other websites or research that he thinks is helpful for them, depending on what each person is looking for.   [41:31] Talking with your doctor about what you are looking for is very helpful.   [41:38] In terms of the transition process, it's an exciting period. We're often going through a lot of big life changes. It could be our first time living away from our parents, having a job, or going to college.   [42:05] Know your own health. Learn about your body. We are the best advocates for ourselves. Only you know what you are feeling. Only you can tell your doctor what you're feeling. Taking ownership of your health will set you up for success for a healthy, long life, achieving your goals. Holly says that sums it up beautifully.    [42:40] Holly says for listeners who are feeling overwhelmed, unsure, or want to find out more about the transition, eoscare.apfed.org is a great site that helps you navigate healthcare for eosinophilic conditions. It also has a tab for building a care team.   [43:05] Ryan says it's great when the guest plugs APFED resources! For those who are looking to learn more about transition of care, please visit apfed.org and check out the links in the show notes below.   [43:25] If you're looking to find specialists, as you're going through this transition process, who treat eosinophilic disorders, we encourage you to use APFED's Specialist Finder, available at apfed.org/specialist.   [43:36] If you would like to hear some recent sessions from the 24th annual Eos Connection conference, we had a session focused on transition of care. Those are available on demand online.    [43:50] If you'd like to connect with others impacted by eosinophilic diseases, please join APFED's online community on the Inspire Network at apfed.org/connections.   [44:00] If you have personally been impacted by eosinophilic disorders and are interested in sharing your experiences, please check out apfed.org/shareyourstory.   [44:09] Ryan thanks Dr. Buckey for joining us today. It was such a great conversation. This will be so helpful for the community. Dr. Buckey says the work of this podcast and of APFED as a whole is so important.   [44:36] Dr. Buckey thanks all the patients and colleagues that he has. He has a job where he walks with a smile on his face every day. It's a privilege to take care of his patients and work with his colleagues. Thank you all for listening today.   [44:56] Holly thanks APFED's Education Partners AstraZeneca, GSK, Sanofi, Regeneron, and Takeda for supporting this episode.   Mentioned in This Episode:   APFED on YouTube, Twitter, Facebook, Pinterest, Instagram Real Talk: Eosinophilic Diseases Podcast apfed.orgapfed.org/specialist apfed.org/connections eoscare.apfed.org Eos Connection 2026 Timothy Buckey, MD, MBE Hospital of the University of Pennsylvania Children's Hospital of Philadelphia Department of Medical Ethics and Health Policy Healthcare Transition Timeline Toolkit Education Partners: This episode of APFED's podcast is brought to you thanks to the support of AstraZeneca, GSK, Sanofi, Regeneron, and Takeda.   Tweetables (Edited):   "I am trained in medical ethics, and I utilize that approach, particularly in shared decision-making, trying to understand my patients' goals and values for their health, … and making a plan that works for them." — Timothy Buckey, MD, MBE   "During this [transition] process, our overarching goal is for an individual to begin to develop ownership of their health so that they can take care of their medications, schedule appointments, and know their bodies." — Timothy Buckey, MD, MBE   "Having a strict age cutoff may ignore the unique aspects of each person and their history. I generally begin that conversation [about transition of care] in the teenage years through the early 20s." — Timothy Buckey, MD, MBE   "Healthcare is very busy, and some clinicians don't have the time to look [at reports] ahead of time, but often, we can take five or ten minutes to look at them at the start of the visit … to be successful and have a comprehensive visit." — Timothy Buckey, MD, MBE   "We are the best advocates for ourselves. Only you know what you are feeling inside. Only you can tell your doctor what you're feeling. Taking ownership of your health will set you up for success for a healthy long life, achieving your goals." — Timothy Buckey, MD, MBE   Guest Bio: Timothy Buckey, MD, MBE, is an allergy and immunology attending physician with a joint faculty position at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia, and a secondary academic appointment in the Department of Medical Ethics and Health Policy. Dr. Buckey completed his allergy and immunology fellowship training at the Hospital of the University of Pennsylvania and the Children's Hospital of Philadelphia. He attended Georgetown University School of Medicine. He also received a Master of Bioethics from the Perelman School of Medicine at the University of Pennsylvania.   Several of Dr. Buckey's research interests include eosinophilic esophagitis, food allergy, medical ethics, and improving access to medical care for vulnerable populations. He was the lead author on one of the largest studies evaluating the rate of eosinophilic esophagitis during food allergy oral immunotherapy. Dr. Buckey was also the lead author on the pivotal 2024 food allergy study, which utilized allergist-performed oral food challenges to demonstrate there are no differences in food allergy outcomes based on race or ethnicity. Dr Buckey has also become a pioneer in investigating the intersection of medical ethics with allergy and immunology. Dr. Buckey developed the first comprehensive ethical framework for the specialty of allergy and immunology to assist clinicians with navigating ethically complex decisions in their clinical practices. He utilizes this patient-centered approach in the clinic when caring for patients with allergic and immunologic conditions of all ages.   Website profile: pennmedicine.org/providers/timothy-buckey

The crimes continue in Southern California, with the murders of Manuela Witthuhn and Janelle Cruz. Paul Holes explains how the offender's violence evolved, how patterns emerged across cases, and how investigators eventually linked the East Area Rapist attacks in Northern California to the Original Night Stalker homicides in the south. For a moment, Paul believes the case may finally be solved. Instead, the investigation enters another long silence. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠antonfloquet.com⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into recent strides made in scientific research, regulatory landscapes, and market dynamics that are shaping the future of healthcare. Starting with a significant breakthrough in cancer treatment, Merck & Co. and Moderna have reported promising results from their Phase 3 melanoma trial. Their investigational mRNA-based vaccine, intismeran autogene, when paired with Keytruda, has shown a substantial reduction in melanoma recurrence risk. This combination exemplifies the growing role of mRNA technology in oncology, moving beyond its initial success with infectious diseases. The synergy between mRNA platforms and immune checkpoint inhibitors like Keytruda underscores a pivotal shift in cancer therapeutics, potentially transforming treatment paradigms with more targeted and personalized approaches. On the regulatory front, Heidi Overton's nomination as the new FDA Commissioner marks a critical juncture for the agency. Her leadership could bring fresh perspectives to drug approval processes at a time when swift regulatory actions are essential to bring innovative therapies to market. This shift in FDA leadership is expected to influence the speed and efficiency with which new treatments reach patients, highlighting the agency's evolving role in balancing innovation with safety. In Singapore, GSK's Blenrep has received approval for use in combination therapies targeting relapsed or refractory multiple myeloma. This antibody-drug conjugate specifically targets the BCMA protein on myeloma cells, offering new hope for patients who have exhausted conventional treatment options. The approval exemplifies ongoing advancements in targeted therapies aimed at improving outcomes for complex cancers. The industry is also witnessing strategic collaborations that could reshape clinical trial access and efficiency. Merck & Co.'s partnership with Sarah Cannon Research Institute aims to enhance community-based oncology trials through the Accelero model, democratizing access to cutting-edge cancer therapies. By bringing trials closer to patients, this initiative could accelerate data collection and recruitment efforts, ultimately benefiting patient outcomes. In manufacturing advancements, Genprex's collaboration with an undisclosed CDMO to scale up its AAV-based diabetes gene therapy production is noteworthy. This partnership is crucial for advancing gene therapy solutions targeting chronic diseases like diabetes, offering potential long-term treatment efficacy through innovative therapeutic platforms. Financially, CSL has experienced a resurgence following increased demand for immunoglobulin products, resulting in stronger-than-expected revenue figures. This rebound highlights the resilience of plasma-derived therapies and signals growing market demand amid fluctuating global health challenges. PitchBook's prediction of a resurgence in biotech venture capital funding further underscores the sector's dynamic nature. This anticipated investment influx is likely to drive demand for CDMOs specializing in cell and gene therapy manufacturing over the next few quarters, reinforcing the industry's growth trajectory. In clinical trial news, Enveda's ENV-308 has successfully cleared its Phase 1 safety trial for obesity management by targeting appetite suppression pathways involving GLP-1 and lac-phe mechanisms. As it progresses to Phase 2 trials, this novel approach represents a significant advancement in addressing metabolic disorders through innovative therapeutic avenues. Conversely, regulatory setbacks continue to challenge manufacturers. Aurobindo's Eugia unit received an FDA warning letter over sterile manufacturing violations, emphasizing the importance of maintaining stringent quality standards within pharmaceutical production processes. Overall, these developments highlight a dynamic industry poised at the intersection of scientific innovation and regulatory evolution. The implications for patient care are profound as new therapies emerge with enhanced efficacy and safety profiles across various disease spectrums. Continuous collaboration between industry players and regulatory bodies remains vital to sustaining momentum and ensuring groundbreaking treatments efficiently reach those in need. That's it for today's briefing on Pharma Daily. Stay tuned as we continue to track these developments and more within this ever-evolving landscape of pharmaceutical and biotech industries. Stay informed and stay ahead!Support the show

After the East Area Rapist disappears from Northern California, an attack with a similar MO happens hundreds of miles away in Goleta. At the time, investigators had no reason to connect it to the Sacramento series. Paul Holes helps us understand the shift into Southern California, the jurisdictional gaps, and the violence of the Lyman and Charlene Smith case. Years later, evidence from this phase will become critical to identifying the Golden State Killer. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠antonfloquet.com⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The S&P 500 is approaching another record high after a few weeks, powered in part by record-breaking options activity and a recovery from July's brief selloff. We will dig into whether the fundamental and technical picture supports this rally or if investors are getting ahead of themselves.Today's Stocks & Topics: GSK plc (GSK), Market Wrap, Stop Orders, S&P Global Inc. (SPGI), “Refine, Baby, Refine”, iShares MSCI Global Gold Miners ETF (RING), S&P 500 Near Record Highs: Is the Stock Market Rally Sustainable in 2026?, The Greenbrier Companies, Inc. (GBX), WisdomTree US Value Fund of Benef Interest (WTV), Vanguard Dividend Appreciation Index Fund Admiral Shares (VDADX).Our Sponsors:* Check out Anthropic and use my code Claude.ai/invest for a great deal: https://www.anthropic.com* Check out Quince and use my code quince.com/INVEST for a great deal: https://www.quince.comAdvertising Inquiries: https://redcircle.com/brands

Today's guest is Clare Hickie, Chief Technology Officer, EMEA at Workday. Founded in 2005, Workday is a leading enterprise software company that provides cloud-based solutions for human capital management (HCM), finance, planning and AI-powered business operations. Workday serves more than 11,500 organizations worldwide, including over 65% of the Fortune 500. Workday helps businesses streamline operations, improve workforce management and make faster, data-driven decisions through its secure, intelligent cloud platform.In her role with Workday, Clare partners with senior business and technology leaders to help organizations transform how they manage people, finance and AI. With more than 30 years of experience in enterprise technology, Clare began her career on the customer side, spending 15 years at GSK before joining Workday in 2018. She is a recognized leader in responsible AI, cloud transformation and enterprise innovation, with a strong focus on building trusted, human-centered AI solutions that deliver measurable business impact.In the episode, Clare discusses:0:00 How AI conversations evolved from skepticism to agentic productivity5:51 Co-creating with customers to deliver proven AI outcomes7:19 How Workday's AI agents deliver significant productivity gains9:06 Creating consistent AI experiences built on a unified platform12:46 Responsible AI requires governance, transparency and risk management17: 33 How trust and responsible AI drive lasting customer adoptionTo find out more about all the great work happening at Workday, check out the website www.workday.com

The East Area Rapist did not stop terrorizing victims when he left their homes. Paul Holes walks us through the phone calls, threats, and psychological cruelty inflicted on the victims long after the attacks. This episode explores fear as part of the offender's pattern. Paul also traces the final Northern California attacks and the moment the series abruptly stops in the north before starting up again somewhere else in the state. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

How can content marketing in a tight niche build the audience that launches your book? And how do you decide whether to hand your self-published bestseller to a traditional publisher. Suzanne Smith shares what she learned in four years of going from blog to book deal. In the intro, how to stand out as a writer in the age of AI [Nathan Barry Show; Interview with Nathan Barry]; thoughts on asset maintenance; Goodreads giveaway on Bones of the Deep (Aug 5-20, 2026) This episode is sponsored by Publisher Rocket, which will help you get your book in front of more Amazon readers so you can spend less time marketing and more time writing. I use Publisher Rocket for researching book titles, categories, and keywords — for new books and for updating my backlist. Check it out at www.PublisherRocket.com This show is also supported by my Patrons. Join my Community at Patreon.com/thecreativepenn Suzanne Smith is the founder of The Independent Landlord, and the bestselling author of The Good Landlord Handbook. You can listen above or on your favorite podcast app or read the notes and links below. Here are the highlights and the full transcript is below. Show Notes How a free blog in a tight niche built the audience for the book Rewriting the book from scratch when the law changed Why speed made self-publishing the only option Building a paid membership after one audience member asked for it Negotiating a Penguin Random House deal with no agent Using AI as a business sidekick, with a control room and an engine room You can find Suzanne at TheIndependentLandlord.com. Transcript of the interview with Suzanne Smith Jo: Suzanne Smith is the founder of The Independent Landlord, and the bestselling author of The Good Landlord Handbook. So welcome to the show, Suzanne. Suzanne: Thank you. Jo: Oh, there's so much to talk about today. But first up— Tell us a bit more about you and your background, and how you got into property and writing after a legal career. Suzanne: Well, I've always loved reading books. In fact, I recently did a French literature degree as a mature student. Being an author was never in the game plan at all. It's not something that I even thought about. I was brought up in New Zealand, so shout out to all the Kiwis and those across the pond in Australia. The thing about it is, Jo, you've lived there yourself. Kiwis are independent, self-reliant and have this great sense of fair play. So that was a very formative experience for me. We moved back to England when I was 16, and I have become thoroughly anglicised since then, but a Kiwi at heart. I always wanted to become a lawyer. New Zealand in some ways on television is quite American, and there was this American programme called The Paper Chase. It was about all of these students at Harvard studying law, and the professor said, “You come here with a skull full of mush and you leave thinking like a lawyer.” I thought, “Oh, I like the sound of that.” I didn't really know what a lawyer was, but everyone seemed to be very happy that I wanted to become one, and then that was it. Jo: So you went into law, and then how did you get into property? Suzanne: So I worked for 25 years as a solicitor. That's like an attorney if you're American. Started off in a law firm, and then I went into pharmaceuticals and I worked for big companies like what is now GSK, GlaxoSmithKline, and small companies as well. When I started out, it was before the internet, before Google. When you're in house, you're very much a generalist. You do a bit of everything. So you help companies grow their business. You're not business prevention, but you're still bound by the code of conduct for solicitors. You've got this role of keeping the company on the right side of the law. Then I had twins, who were born about five years after I became a lawyer, and I decided to work part-time for a while and did an MBA when they were little, part-time through the Open University. I know Jonathan is doing one at the moment. Jo: Yes. He's finished, so that's exciting. Suzanne: That was transformational for me, because I had probably been thinking a bit too much as a lawyer, and it helped me to broaden my view of the world and understand all sorts of things. Sso I continued going up the greasy pole, and then for my last job, in 2015, I joined a biotech company in Cambridge, England, as general counsel and company secretary. It was a long way from home, about two, three hours' drive from home. So I decided to buy a flat, an apartment, and to stay there in the week. I thought to myself, “Well, when I leave this company, I can let it out as a buy-to-let,” but actually as a landlord. So I stayed there for five years, and then when I left, I let out the property. The reason why I decided to leave law after 25 years, I had what I call a sliding doors moment, like in the film. I was 50. I was on holiday with my husband, and we'd probably had one too many rum cocktails. And he said to me, “Well, what do you want to be doing with your life? What would you do if you could do anything?” I was thinking, “Well, I've done law. I want to do something else now.” I didn't really know what that was, and I'd always been thinking about studying French properly, and that's when I left. So I decided, 18 months later, I left to do a French degree at King's College London, full-time. I was the only old person there with lots of 18-year-olds. When I did that, I was able to cash in my share options because I was a good leaver. I retired, and so I started buying properties to let out and became a landlord, without really thinking too much about it, and I used letting agents. They were fine to begin with, but I didn't really have a game plan or anything like that. What I realised is that when I tried to research things online, I couldn't really find anything that was terribly helpful. It was either quite general or it was very legal. So after a while… I became a landlord in 2019. I had the idea, why don't I set up a blog? And this is August 2022, so just four years ago. My husband came up with the idea of the name, The Independent Landlord, because it's that Kiwi spirit, being very independent. I thought, “Right, I'm not going to charge anyone for it. It's a hobby. It's not a business. I'm going to pay it forward and help, use my legal training, practical legal approach, and practical common sense, by doing this blog.” Almost exactly four years ago, I sent my first newsletter to 13 people. Jo: Woo-hoo. Suzanne: And I sent one last week to over 18,000. So it's been quite a journey. Jo: Wow, this is so great. I love this. There's so much in there. The turning 50 and then doing a degree. My master's in death is a little different to your French literature, but I like it. So I love this, and buying properties, starting it on the side, not a business at first, and growing the audience, and obviously you've put so much work in. Then you decide to write a book. So talk about that, because an online blog, although I'm sure your articles and everything were super useful, it's very different to write a blog than a book. So talk about your challenges in writing. Why did you decide to do a book in the first place? Suzanne: Again, I was an accidental landlord, is what they call it when you let a property when you didn't intend to buy it as a buy-to-let, which I did with my Cambridge flat. And I became, in many respects, an accidental author. So I was having a conversation with my husband again and I was saying I'd done this lead magnet to get people to sign up to my newsletter, and a big new law was going through Parliament at the time, called the Renters Reform Bill, that was going to completely transform the way landlords operate. I was saying to my husband, “Oh, I need to update my lead magnet, a little ebook, to explain the new law.” He looked at me and said, “Well, why don't you do a proper book? Write a book.” This was on the 29th of September, 2023. The reason why I mention that is that I thought, “Wow, what a great idea,” and my head was bursting. I went onto Google, and guess what I downloaded on the 1st of October? Jo: My blueprint? Suzanne: Exactly. I found you immediately, the Author Blueprint, and I downloaded it. I checked: on the 1st of October, 2023. Then I listened to almost… well, I think I went back several years on your podcast, just trying to understand. I'm like that. When I try and do something, I just try and learn everything that there is to know about it. So I started writing the book, and I guess the first challenge was I write quickly, and I'm used to writing for people who aren't lawyers, being in-house. So I thought I needed to have a structure. The structure was easy in many respects because, a bit of business at the end, and then you can go through a tenancy. I thought it was important to have a narrative thread all the way through it, just to bring it together. This is the literature degree coming in here. I thought that the mission for everything I do, the reason why I started doing this, is to help landlords, but also to help the experience of renting that people have in England. It's very specific for English law. And to help improve the private rented sector. So that's why I originally set up my blog for free, and I wanted, when people went onto Google, they could find something sensible and very detailed from me. My blog posts were… Well, I've now got over 400,000 words on my blog, so it's a substantial piece of work that is out there free of charge. So what I decided to do was to bring this narrative thread, I call it the good landlord ethos, to the book. Then I wrote very quickly, and I had a pretty good draft by April 2024, because we were all thinking that the law was going to change very soon. But then there was an election, and in the end the government changed and the legislation changed completely, so I had to rewrite the book and start again. So I think that my biggest challenge was that my subject matter, the new law, changed. Because I wanted to publish this book that explained to people practically what they have to do, and make it really straightforward, keeping out of politics, because it is a very politically charged area. I wanted to write it so it's a manual, somebody could literally follow it. So I used an editor, and I did write the book twice. I had a beta reader who is another lawyer, and a landlord as well. Then I got to the get-the-damn-thing-done stage. The really tedious bit of all the typos at the end. Jo: Yes, the finishing energy to get it out there. So at that point, obviously you'd found my blueprint, so you were learning about the indie way of doing things. Did you always decide to self-publish? How did you think about publishing? What were your challenges in publishing? Suzanne: It never occurred to me not to self-publish, because the new law came into effect on the 1st of May, 2026. The law and the details that I needed for the book were finalised in January, and I published on Amazon on the 5th of March, so I had to go so quickly. Even though I'd got a lot of it written, the last bit came in January, and so I needed speed. I knew that for landlords to be able to have something that they can use straightaway to help get them ready for it, and then use as a manual afterwards, I had to be first. Jo: Sorry, just on the year. Was it '24? You said '26. You meant May— Suzanne: 2024? No, no, because I actually published it this year. What happened in 2024, I had the first draft ready, but then I had to do another draft because the law changed when the Labour government came in. Jo: Right. Suzanne: The Renters Reform Bill turned into the Renters' Rights Bill. So I had to rewrite the book. So I finished however many drafts at the end of January 2026. Then it went to an editor, et cetera, et cetera, and I managed to get the book ready for a proof, to get the proof printed, towards the end of February. So it was really quick to go from the law being sufficiently finalised for me to write a book in January, and then having it ready in just over a month. There is no way that I could have done that if I'd gone to a traditional publisher. It didn't even occur to me to go, because I didn't want to be going touting around my book and, “Please publish me,” et cetera. It's just not me. I'm the independent landlord, and that moved very easily to being the independent publisher. So I learnt how to do all the publishing. And a huge thanks: I joined your Patreon and I was a very good student. I went through everything systematically and followed your playbook, and used Vellum and BookFunnel and all the other tools. So I decided to go on Amazon as well as have my own Shopify store, which just about killed me. Jo: I was going to say, you are an excellent student. You really like learning, but you also put this into practice, which is why I also wanted to talk to you. You haven't just talked about all this. You've literally done everything. Suzanne: Sometimes it was like my head was going to burst. Luckily, Claude upped his game earlier this year when we got the Opus 4.5. I didn't use AI really until this year. I decided I need to do exercise all the time, and have that as a have-to-do, because my head was spinning all the time with all these different things. So I would go to the gym, go to a spin class, and then I would walk out with my phone on, with the Claude app, and dictate a stream of consciousness into it. “Oh, I need to do this, or what about that? Oh, I just remembered about this. Oh, I've had this idea, blah.” And then said, “Make sense of it for me, Claude.” So it was very much as a thinking partner, because when you're writing your first book, it's bad enough, but when you're learning how to publish… Even, like, when I got the first proof of the book back from BookVault, I realised that all the footnotes—I have 114 footnotes in my book, and that, again, is the recent degree there—and the formatting had gone skew-whiff. Apparently it was an issue with Vellum, and they were really lovely and they sorted it straight out for me. So it shows: always get a proof of the book. They were able to sort that out very quickly, and BookVault were very quick in getting me another proof, because you can shortcut it and just pay to get a very quick delivery. Amazon, on the other hand, was really slow. It took a week. So I actually published earlier on my Shopify store for my members, of my membership, and I gave them a discount. Then I finally got it onto Amazon on the 5th of March. There are all these different skills you're having to learn. The Shopify store I found very hard, and there was all the tax, because I'm VAT registered. So I think I'm still recovering. Jo: You're still recovering. I wouldn't normally recommend a Shopify store for someone with their first book, doing first of everything. But, as you say, you're someone who learns a lot, puts it into practice, and— I think you were pretty determined to do that because you had a community as well, right? Suzanne: Exactly, yes. The big subscriber list. I think that's why the book did so well. So in the first week, because I met you at the Indie Author Lab put on by— Jo: Yes, London Book Fair, yes. Suzanne: Yes, the Alliance of Independent Authors. I met you there, and it was just my first week, and I had 1,000 sales in the first week. That was because of my audience. I'd been going on about the fact that I'm writing this book for two and a half years, because that's how long it took me to do. So I had a wait list for it, and I had a thing on my website, a landing page on my website, saying how good the book was and why it's the best thing for the Renters' Rights Act. Then I went onto Google, and I think I sent you a screenshot of this at the time. I put into Google, “What's the best book for the Renters' Rights Act for landlords in England?” And it came up with me as a featured snippet, and I hadn't even published it at that time. It was just about there. So the blog really helped, because I'd become an authority on the Renters' Rights Act. Even though I'm not a practising solicitor any more, I spent all my time reading the damn thing, and it is a very complicated bit of legislation. Funnily enough, I have ruffled a lot of feathers. People have even said about me behind my back, “What does she know? She's only got four properties.” But I just took no notice. I thought, “I'm going to try and use my legal brain and my understanding of what it's like being a landlord, there with the rubber gloves cleaning an oven when people have moved out, and try and write something that's not trying to sell anything else, and to help people.” And then it got picked up. Jo: Yes. Wait, let's just slow down. Slow down, because we will get onto that in a minute. But let's just come back to that launch. So as we talked about, you've had a blog for five years— Suzanne: It was three and a half by then. Jo: Three and a half years you've been blogging, but hundreds of thousands of words of useful information. So you've essentially done content marketing. You've attracted people. You had a lead magnet. You got them on your email list. You told them that you were writing a book. You got a sort of pre-sales list up. So that's an email list. You've got a blog. Did you do anything else in terms of marketing? Suzanne: I had YouTube, a big YouTube channel. I'd only set it up at the end of 2024, and I'd had half a million views. And again, just very straightforward advice, and without all the scaremongering and politics. I deliberately keep out of it all. A lot of people joined my newsletter as a result of that. Also a year ago, exactly today, I was running a Facebook group, which was a lot of hard work. There were a few thousand people in it, but there are often a lot of people going in there trying to sell things: insurance, eviction specialists and things. And there was also a lot of people just being unpleasant to other people. I was getting fed up with it. It was taking me a lot of time, and I was doing a lot of speaking events and trying to explain what this new law was doing, and wearing myself out. I'm an extrovert, but even I find speaking events absolutely exhausting, because it's like everything gets sucked out of you. It's strange. Then somebody came up to me in July last year and said, “Suzanne, can you set up a membership?” I said, “Well, landlords aren't going to pay for that.” And they said, “Yes, they will. You build it and they will come.” I asked ChatGPT and thought about it. I asked ChatGPT, who I was dating at the time, now exclusively with Claude, but I know Claude has other people in his life. But I'm very much set with Claude Fable at the moment. So I asked ChatGPT, how can I go about setting up a membership? And I mentioned your one and said, “Should I do it on Patreon?” And then he came back with: go for Circle. So I set up a membership on Circle, exactly a year ago. In fact, it's the anniversary of my first member yesterday. hTe rules I had were, no selling. So I don't sell, no affiliate links, no one else can sell anything, and we have to be supportive. No negativity, no politics. So what it's become, it's like the senior common room of the private rented sector, with landlords, lawyers, letting agents. There's a fantastic forum in there. It's not me doing it, it's peer-to-peer. I have twice-monthly live streams where people can ask me questions. I wonder where I got that from. No, I very much modelled it on your Patreon, but on a different platform. I have courses in there as well. So that has really grown. I launched it in July, and by September, October, I'd gone past the VAT threshold, which has complicated everything, but it means my business now is this membership. I really enjoy doing it, and there hasn't been all the negativity that you have in a Facebook group. So I had them as… talk about your thousand fans. There are about 1,500 in the membership, and their support really helped the launch of my book, as well as the wider people who get my free newsletter. Jo: Yes. Suzanne: So it's all different types of content marketing. Jo: Y, but I do love this. And of course, if people are wondering, I joined Patreon back in 2014, I think it might have even been before that, and there weren't too many places back then to run communities. It wasn't even really a community at the time, it was a sort of, almost a “give me a bit of support for the podcast.” So things have changed a lot in terms of communities, and obviously you went with Circle, which is great. Patreon is slightly different now, and some people are using Substack for something similar. So that's just on the platform, but on the business: early on in our conversation you said, “I wasn't going to have a business. It wasn't a business. It was just putting stuff out there, helping other people,” and then your audience asked for this membership. And so now it is a business, right? Suzanne: Yes, it is. Jo: And you've got a book and all of this. So are you happy with the change to a business? Because obviously you have to treat it quite differently. Suzanne: Yes, I am, because I think to begin with, I was just doing it one or two days a week. I was actually studying a master's in French literature part-time, and I then found that I was enjoying the blog more than the master's, so I dumped the master's after the first year. But after getting 88% for one of my dissertations, which interestingly was on the translation of a Simone de Beauvoir book into English, and the publisher who's got that now is Random House, but that's another thing. Anyway, so I decided to give up my master's and double down and work full-time on the blog. People were paying to help me with all the big fees and things, the big tech stack, Buy Me a Coffee. I was doing a little bit of consulting and things. I was working six, seven days a week. I was treating it like a business in terms of quality and my effort, but it wasn't a business in terms of revenue. Then it just all came together, and this person said, “Set up a membership,” and I thought, “That's what I'm going to do. I'm now going to put it on a business setting.” I've got an MBA, I know how to do it, and people thought I planned it, but I didn't. It just happened. So now I do very much treat it as a business, but I still don't advertise. I don't allow people to advertise with me, because I want to be independent. If I recommend something, I want people to believe it's me recommending it, not just because someone's paying me, which can be a big issue in the landlord area. Jo: Oh, in any industry. I get pitched every day with loads of random things that people are like, “Oh, a dollar a click or whatever, if you send this to your list.” And it's like, seriously? Just stop it already. I did just want to add there: somebody asked you, they said, “You should have a community,” and that sparked that idea. I just wanted to acknowledge that my Patreon came from Jim Kukral. Some of you will remember, who've been around a long time. Jim Kukral came on my blog around sort of 2013. Amanda Palmer had just put out a book called The Art of Asking, and I was doing a lot of unpaid work on the podcast at the time, and I was either going to give it up or I had to fund it somehow. Jim said, “You should do a Patreon.” And I was like, “Oh, no, I hate asking for money.” So at the time I just felt, oh, weird. Then I was like, “No, I do all this work,” as you were saying. Now the Patreon has changed so much in terms of what it is, but it is the backbone of my business, too. So I love that you listened to one of your fans who said what they wanted, and I love that I've listened as well. Sometimes we just have to listen to those urges, don't we, to take things on? Suzanne: Yes, absolutely. In some ways I didn't really back myself before. I thought, “No one's going to pay for this.” Then the more you give, the more they want. Jo: Yes. Suzanne: What I've been really working on now is having boundaries, because there were two big kind of mottos that I picked up when I was working in pharmaceuticals. One was from a head of the business. He was Canadian, and he was always saying, “You've got to skate to where the puck is heading.” Jo: That's Wayne Gretzky, is it? Suzanne: Exactly. Yes. He would always say it, and so that's what I've done with my blog and my book. When I write things, I don't pay for any tools. I don't do keyword searches and all that. I just think, I do one blog post per topic, and I'm going to guess what people are going to be searching for soon, and I build up all this content around it. That's why most of my blog pages are top five. I've had no advertising. I haven't asked for any backlinks. I don't do it. People backlink to it because it's useful. So that was the first thing, is skate to where the puck is heading, and that was my approach with the book. I knew people would need this book from around May, and they'll need it forever, because it is so complicated and regulated, the rules for being a landlord in England. So that was the first one. The second thing was: when you take something on, you've got to let something go. One in, one out. I found that I was taking on so many different things, and I've just been cutting back, because I can't be doing all the speaking, I can't be answering people's emails. So I now don't do emails. If people want my advice on something, they ask me in the hub, at the twice-monthly live streams. Sometimes I answer in the forums, but I don't have time. When there are 2.4 million landlords in the UK, and even with our 18,000 on my newsletter, I could spend, and I did, I used to spend all my time replying to emails. So anyway, there are the things. Oh, and there was a third one, which is: attract, don't chase. One of my friends gave me that advice and that's exactly what my approach has been. I just don't chase for anything. I just put the stuff there and then build it and they will come. Jo: Yes, and I think another thing is the power of the niche. It's so clear that what you write about, the people you are aiming at, you have an extremely tight target market. That is both a strength and obviously a weakness, because they're the only people. But as you say, there's more than enough of those people for a community, for the book you have. From my own perspective, that's the same for me, the power of the niche. That's how I have a successful podcast, for example, because of that reason. I think you're like a poster child of what a non-fiction author should do. What I like is that you didn't go, “Oh, where's a niche where I could make money?” and then jump in. You've gone about this in a kind of slightly accidental way, but now you're leaning in and this uses all your skills. So this really is a great example of the power of the niche and then making the most of it. But let's move on to what then happened, and— What happened with the book deal? Suzanne: Wow. So you and I met each other on whatever day that was in March at the Indie Author Lab, and the following day I got an email, via my website on a contact form, from Penguin Random House saying, “We love the book. We love the mission, its values,” all this kind of thing. And I was thinking, “Oh, it's another one of those. Must be an—” Jo: AI spam bot, right? Suzanne: Yes, and I remember I sent you a screenshot of it, and then I checked her out on LinkedIn and thought, “Okay, there is somebody with that name there.” You're always saying, and Orna Ross and everyone are always saying, “Watch out for scams.” And in fact, Penguin Random House even this weekend on Instagram put out something saying, “There are lots of people impersonating us.” So I didn't take it too seriously, and it was something like, “Oh, would you be interested in us publishing your book?” And I thought, and I laughed. It was like, no, this is too good to be true. So I replied and said… Oh, I said, “Well, thank you so much. The Renters' Rights Act…” And so this is like the second week in March. “The Renters' Rights Act comes into effect on the 1st of May. If you want to publish it, you're going to need to get your skates on.” I literally did say that. Then she arranged a meeting with me the next day, on the Friday. I still was very dubious about it, and I had a think about it. What helped me, and I have the little booklet here: at the Author Lab, we did some work at the beginning, and Orna said, “Put your phones away.” And it was like, “What? Put my phone away?” Then we had to do this definition of success, and our passion, and our mission, and our purpose. I wrote down things like, I want to help landlords, and in so doing, help improve the private rented sector. I get pleasure from helping people. I want to improve standards and use my legal and practical skills, et cetera. So I thought, “Okay, what is my purpose of doing this book?” It isn't really to make money, because going with Penguin, you wouldn't do that for financial reasons, because you'd make very little money. So I thought, what is my why? My why is I want as many people to read this book as possible. And I've managed to sell a few thousand copies, but there are 2.4 million landlords, and they all need to understand this book, and the only way that I can get it out there, apart from doing ads, is to get it out in bookstores. So I thought about it, and then said, “Yes, I will do it, because I want to get the book out there.” So it's distribution. It's going to be published on the 6th of August, which is really quick, bearing in mind they contacted me in the middle of March. It's exactly the same book, it's just got different copyright wording and different blurb, different paper. Same cover, because I managed to find a fantastic cover person to do it. So they've kept everything the same. So we negotiated that book. I have no agent. They came to me. It's the attract, don't chase. I just put my lawyer hat on, and because one licence is very much like another one… I did turn down their first offer. Jo: Well done. Good negotiation. Suzanne: My daughter said to me, who's an adult daughter, she said, “But it's Penguin.” And I said, “Well, no, but it doesn't work for me.” So I had a call with them, and then they came up with something that worked for me a bit more. I did have to concede on a few things, like I can't sell it in my Shopify store. But in some ways, that was a blessing in disguise, because it means I don't get any more “Where's my book?” emails. Jo: Yes, exactly. Pros and cons of everything, basically. Suzanne: I have very clear rights to get it back. If I want it back, I can get it back and I don't have to give a reason. They're lovely. They have been really very wonderful. When I went up there a month or so ago, they gave me this book bag, and it's got on it, “I'm published by Penguin,” and I burst into tears. Jo: Aw. That's nice. Suzanne: I don't know, it just seemed like such a big deal. Because up until then I was just being all very lawyerly and task-orientated. Then I thought, “Oh my goodness,” and then it dawned on me. So I'm now in this interim period where I've taken it off Amazon and off my Shopify store, and I feel very maternalistic towards the book because, you know, it took me two and a half years, which is longer than a pregnancy. Obviously it's not a child, but it's like my book child. I've sent it off with a backpack and a drink and some snacks, and I hope that they look after him, my book. The day I took it off Amazon it was still number one. And a big shout-out to Publisher Rocket, by the way. Jo: Yes. Very, very useful for niche publishing. Suzanne: Very. It helped me choose the right niche categories. So it was number one on at least one category, often six, all the way through. I thought, “Well, it's over to them now.” They're very lovely people. They've given me some marketing assets, as they call it, some swanky graphics and things to use. We'll have to see what we do in terms of marketing. I don't mind doing marketing. I'm on LinkedIn quite a bit, and my whole blog is marketing. What I've been doing is updating my blog to include one of these graphics and to mention the book, and I got Claude to help me draft the code so it looked right. So I've been going through all of my blog posts and sending people to Amazon rather than to my Shopify store. It is mixed feelings, because I care about my book. I put a lot of effort, a lot of love, a lot of tears. No, not tears, but I put a lot of effort into it, and it's out of my control now. Jo: Yes, you said it's over to them, but obviously you will still be creating content around this topic, so you'll probably still be the biggest driver of book sales. Suzanne: Yes. Jo: Are they also suggesting, for example, a podcast tour, like pitching for podcasts? Are they going to assign you some PR? Because, also if people don't know, as we are recording this, we have a new prime minister who wants to do various things. You said no politics, but this is obviously a political thing. So you have the potential to go on a lot of different podcasts, media, talking about this, becoming almost a talking head in this kind of area. So are you angling for all that, and is that in your contract, or is it literally just going to be whatever you want to do? Suzanne: That's not in the contract. What's in the contract is very minimal. I think I've already done what I'm supposed to do. They are pitching for me to go on podcasts and things. I'll tell you a really funny coincidence. So we now have a new Prime Minister, Andy Burnham, and when he was Mayor of Greater Manchester, he set up something called the Good Landlord Charter. I actually talk about it in the book, and I quote him in my book saying that good landlords mean people trying to do the right thing, or something like that. And I coincidentally came up with the same name, The Good Landlord Handbook. I'd already had the book title for a long time. So this idea of good and landlord coming together, the adjective good as opposed to criminal or rogue, and the cover being green. I'm wanting to change the narrative so it's the norm to have a good landlord, and to help people become good landlords. Or if they're good landlords, help them to understand the new rules, because the new rules are very complicated. So what I don't get involved in is this right or wrong. Is it right that landlords can't do this or have to do this? Because as an in-house lawyer, it doesn't really matter what I think about the law. GDPR, goodness me. Jo: Oh, dear. Let's not start on GDPR. Suzanne: No, exactly. Because we've just got to suck it up. I liken it to the grief cycle, that people have been going through so much change and you have the anger, the depression— Jo: Denial. Suzanne: Bargaining, the denial, and then you get to acceptance. For some people, the acceptance means they want to stop doing it. If you want to accept it and stay, you need to understand the rules. So I've deliberately just kept very practical and have kept out of all the politics of it. I have, funnily enough, become involved because I'm now seen as an expert on the Renters' Rights Act. I've worked behind the scenes with the government to help, and give comment on government guidance for landlords. I was even invited to a reception to mark the passing of the Renters' Rights Act at Downing Street with the previous prime minister, all whilst staying apolitical. I won't let anyone make me be a mouthpiece for their political view. It's more, we just have to do this if we want to continue doing it. I've been very clear on that. Jo: It's interesting you mention the grief cycle there, and you've also mentioned Claude and ChatGPT. I wonder if you might also just comment on use of AI for authors and for marketing and all this. Also with legal stuff, because for me now, if I'm looking at a particular legal thing, I tend to ask Claude. I'm like, “Can you just explain this?” or upload a contract or whatever. Although it is not legal advice, it can be quite useful. So give us your thoughts on using AI as a sidekick in your author business and also for wider life. Suzanne: I now struggle to think what life would be like without Claude. I don't use Claude to write, at all, because I have a very particular voice and a turn of phrase, and if ever Claude writes something for me, it doesn't sound like me. It flattens me, and it makes me sound a bit American. So I don't do that. I've used it in the back end of the business. For instance, my blog was down, and there was something called a recursive bot, which I don't even know what it was, and Claude helped me fix it for free. I went through, I did screenshots. When I did an ElevenLabs audiobook and did it all myself, I was literally, for every screenshot, showing it to Claude. Claude said, “Do this, press this, press that.” So I have all these different projects set up. One is the control room, where it's for my strategic thinking. If I have an idea, I want to think about something, I put it in there. I have the engine room, which is for everything techy. Like when I had the recursive bot, or if I'm wanting to have some code on the website to make it look a particular way. Then I have other things for different subjects, and I put all the resources in there, and I use it a lot as a thinking partner. I've noticed that Fable doesn't hallucinate as much, but the Opus used to. There's something called rental discrimination, and it was proofreading and said, “No, it's not rental discrimination, it's rental income discrimination,” and that was just a load of rubbish. So I would never let it go and change things without me looking at it. I went on one of your webinars a month or so ago about MCPs and all the connectors, which is fantastic. It can go into my community and pull out all the questions for one of my live streams and put it into a document in order, by theme, for instance. It can look at my MailerLite, because that's where my newsletter is with, and analyse the different open rates and click rates and things. It's so good for analysing everything, all the book sales. It helped me with my negotiation with Penguin, and it is pretty good on law. It has sometimes hallucinated things, but not so much now. I think with anything, you've always got to go back to the primary source, and this is what we learn in academia: you have to check the primary source yourself. I have a bit of a magpie brain. I'm very much a discovery writer, like you, and things occur to me as I'm doing it. I think that Claude, at the moment, is incredible. I've been quite open about it on social media that I have Claude as a business partner. I'm a solopreneur, or whatever the word is. I have quite a big business now, and lots of different things, and it's just me doing it, because I can ask Claude how to do this, and how to do that. Claude can go and check my emails and tell me, is there somebody I've not replied to, which helps a lot. Jo: Yes. I think it's empowering as a solopreneur as such. You talk there about the fixing the tech stuff. I have my web host come to me and say, “Look, you're getting so much traffic and bot stuff, and we need to put this thing in, and it's going to be $120 extra a month.” I was like, “Can you just give me an hour? I'll get back to you.” And then I just had Claude code up, and I was like, “Analyse this and tell me what we can do.” It was like, “No, you just need to flip this switch and do that.” And I'm like, “Okay, fair enough.” Then the guy said, “Oh, no, okay, actually you don't need it.” Just stuff like that. As a solopreneur, you're either going to pay somebody technically quite a lot of money, or you can get Claude or ChatGPT. We should say, the ChatGPT Sol is very good, like the Claude Fable, for example. So, yes, using it as a sidekick. I love your control room and your engine room projects as well. That's a great way of doing it. Suzanne: I wouldn't be without it now, and I would have published the book a lot later without Claude, because Claude was helping me with the Shopify store and all the many steps of things. It saved me real time. It is just fantastic. I think, like now when I'm updating my blog, I have a connection between Claude and my blog. Claude can go in, I can give it my Google Search Console results for the page: what should I change, are the headings right? All this kind of thing. And it will give me a view on every single page, which is incredible. Jo: And YouTube, and just everything. Just super useful for that business sidekick. That's what I want authors to think. I feel like authors get so obsessed with the creative side with AI, whereas actually, people like you and me, we're using it as that engine room for the solo business, which is what I love. So we're out of time. I did want to ask one more thing, which is, one of the biggest issues with a specific book like yours is when they change the law again. So do you have a plan in place for if, say, a new government changes the law again? Will you just be updating the book over time? Suzanne: I think that there'll need to be a new edition of the book in three years' time, and I've spoken to Penguin about it. Not all of this new law has been implemented, and there's going to be case law and things. So I expect that I will update the book every few years. I have some other ideas for books as well, but for the moment, I'm just taking a bit of a break. You always say we've got to refill our creative well. I really feel like that at the moment. Recently I've just got myself a personal mobile phone so that I can turn off my work one when I'm on holiday and actually take time off. Because for all the time that I was doing the book, basically from Christmas until May, I didn't have one day off. That is not good. So I'm just trying to be a bit more balanced. I had an idea to write another book for summer, but I've just decided not to, and I'm going to leave it until I feel the urge again. Jo: Oh, well done. Suzanne: Which will come. Jo: Yes, well done. Suzanne: I think there's nothing wrong with that. We just need to think what's right for us. I'm 58. So I want to be able to have time to enjoy things and not be working all the time. Jo: No, that's great. It's a sustainable business. So where can people find you and the book and your community online? Suzanne: The easiest way to find me is theindependentlandlord.com. Or if you put Suzanne Smith and landlord into Google, you'll find me as well, and there's a link on there to the book, The Good Landlord Handbook. In the community, there's a link to that on my website as well. Jo: Brilliant. Well, thanks so much for your time, Suzanne. That was great. Suzanne: Thank you.The post From Blog To Community To Book: A Non-Fiction Author's Journey With Suzanne Smith first appeared on The Creative Penn.

As fear spreads through Sacramento, the public demands answers. Communities hold meetings. Newspapers cover the case. And all the while, Paul Holes believes the East Area Rapist was likely watching closely. In this episode, we examine a chilling turning point in the series: the first known attack with a man present in the home, and the possibility that the offender targeted that couple after a town hall comment. The case draws more public attention, and the crimes become more calculated. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The case moves into Cordova Meadows, a Sacramento-area neighborhood that became key to understanding the East Area Rapist. Through maps, geography, victimology, and old case files, Paul Holes explains how the offender's movements revealed familiarity, planning, and confidence. What may have looked random from the outside begins to look very different when Paul studies the streets, fences, backyards, and anchor points that help shape the investigation. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

The crimes move north, and a new name emerges: the East Area Rapist. Paul Holes explains how the offender's behavior changed after Visalia, how early attacks in the Sacramento area unfolded, and how investigators struggled to understand whether they were dealing with a new offender or just someone who had evolved. As the crime spree expands, Paul begins to unpack one of the most disturbing facts of the case: Joseph DeAngelo was a police officer. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Paul Holes begins the story in 1970s Visalia, California, when the Golden State Killer was just beginning to make a name for himself. Before the East Area Rapist, before the Original Night Stalker, there was the Visalia Ransacker, a prolific offender breaking into homes and leaving fear behind. Paul walks Yeardley, Dan, and Dave through the early crimes, the killing of Claude Snelling, the shooting of Officer McGowan, and the case files that first pulled Paul into what would become a career-defining 24-year pursuit. Want to hear the entire series right now? Join Super Duper Fam at ⁠⁠⁠⁠⁠smalltowndicks.com/superfam⁠⁠⁠⁠⁠ for access to the full ad-free binge feed, and use promo code GSK for your first month free. What is Chasing the Golden State Killer with Paul Holes? This is a 10-part limited series from Small Town Dicks, Paul Holes tells the full story of his 24-year pursuit of the Golden State Killer. Across ten episodes, Paul joins Yeardley, Dan, and Dave for a firsthand account of one of the most significant cold case investigations in American history. From the early crimes of the Visalia Ransacker to the East Area Rapist attacks, the Southern California homicides, and the DNA breakthrough that finally identified Joseph DeAngelo, Paul walks listeners through the evidence, the setbacks, the mistakes, and the personal toll of doggedly pursuing a case for decades. This is a rare, firsthand account of the work, the weight, and the persistence behind a case that forever changed the way crimes are investigated.  Small Town Dicks Presents: Chasing the Golden State Killer with Paul Holes is an Audio 99 production. Written by Paul Holes and featuring Detective Dan, Detective Dave, and Yeardley Smith. Produced by Jessica Halstead and Monika Scott. Executive produced by Ben Cornwell and Yeardley Smith. Edited by Katie McMurran and Soren Begin, with additional editing by Cristina Bracamontes. Sound supervision by Logan Heftel. Design and social media by Andrew Polk. Theme music composed by Logan Heftel. Photo courtesy of Anton Floquet | ⁠⁠⁠⁠⁠antonfloquet.com⁠⁠⁠⁠ To support the making of this podcast, visit smalltowndicks.com/superfam and hit the “Join” button. Stream all episodes at smalltowndicks.com/goldenstatekiller. Learn more about your ad choices. Visit podcastchoices.com/adchoices